var title_f10_40_10880="Embryonic development";
var content_f10_40_10880=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F65456&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F65456&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 617px\">",
"   <div class=\"ttl\">",
"    Embryonic development",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 597px; height: 517px; background-image: url(data:image/gif;base64,R0lGODlhVQIFAuYAAP///4CAgAAAAP//zH9/Zn9/fz8/P0BAQL+/v0Bm/9lmZuaZmcDN//LNzYCZ/+/v7y8vL9/f38/Pz09PT19fX5+fnx8fH6+vr/Dz/0CMZjBZ/9DZ/8DAwMwzM29vb2CA//zz84+PjwAz/8DZzeDm/1Bz/6Cz/9+AgPnm5txzc4CzmXCN/+yzs/bZ2dZZWSBN/7DA/6DGszCDWZCm/+mmpuDs5tDj2dJNTWCggHCpjT8/Mw8PD+KNjfD286CgoDAwMLDQwNDQ0BBA//Dw8ABmM+/AwJC8plCWcyB5TWBgYM9AQCAgIFBQUBBwQLCwsODg4JCQkHBwcBAQEAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAABVAgUCAAf/gACCg4SFhoeIiYqLjI2Oj5CRkpOUlZaXmJmam5ydnp+goaKjpKWmp6ipqqusra6vsLGys7S1tre4ubq7vL2+v8DBwsPExcbHyMnKy8zNzs/Q0dLT1NXW19jZ2tvc3d7f4OHi4+Tl5ufo6err7O3u7/Dx8vP09fb3+Pn6+/z9/v8AAwocSLCgwYMIEypcyLChw4cQI0qcSLGixYsYM2q0xCGAx48gQ4ocSbKkyZMoU6pcybKly5cwY8qcSbOmzZs4c+rcybMnB1EBDvQcWvKAUKJIkypdetMo06dQo0qdelIo0ADMPG7UpXVru66gwCYT65UW2bLnznJSW4wtWldu/9+Gi4uJbjC7clHhzbttLyW/vQDzvTrYnOBIZxkoxiDscCXFijcsSrAJg+RUJlZU2qAZUWZZjndBZkACkgkTpDCUuDxpBetCql9jC+3orAgHDl7I5kVb0m3cqBWJ2MT5EW5MGDQwpsSAcqISDGL1xvXbQfRCxw9lRzQck4MZlhJcP7TBubbpi2wLgkHZAQn3GD4kcHDIRIIPpUmYYECfhHzrANg3nyAmwFBCCaUFeF+CtWFlSneDFHggBg4kAB4AItjXmQkbzAADfYI4gAGF8zHGAAzyRadfiPe9xl4CMACQwHwkMFDCfYyRuEJw7K2GXXAmlMaAZIoB0ONlRwLQHP8AFG4QH44AkGAeXA4yAyGLHzA2o3s2Qrkdk/JlycBtQcrno4IfgLjBjTESkpwgRZIQ44pPglinIOIZCV6FZ34w3mxVfqJegCVgSKMG0a0AYoQlYMDAC0oKUQJ9iAKQppKMlYBaAitgMMMHhDoK6SPoPVLdpp3OgCgGL5QmQnQlgJfAC9ZVyoAGltLnAKgVkrABpEuuAOoGbQLwKwYrfuCnZaV9CoCiChrZKAkvLCcIriHSd5+MJ05brYHIVrukBqDGauRlCVjbSqm1vFoktOxZuuwGzfK6KADmwkDvq/RK9qu0yA5HggYkYJDnIB/CSdkKuB5XKbQPa3uiEB0WSiz/nJ1lwy4itjmwgm4YCvIrbvLJOCO+1yWwwZLGYnvce7NKrCRl0OG5gYDBJbIxI+4Oye3MeEbX3ZIHmwDqB6gJMYjS2Q23pBDqCkKCEDNcl52nJWhAGdRAl5Bmbn+a15x/uCrtNW4v2Ph12s0pK8gHJcDAIICv7CxLdQAIgZsDw109Q9bt3Qu33IJAaHQCw8VdOAAzzFfhvXSH3CJ0I++qMq2WyzgDyCZowCEhU15jdyG2Fbm4kohGVsjB4rHMMm7UxnhcnkSn/Gd6gY5y5c8s5zk0ZQfnvYHSIS/eNNC7D/Ke1gBkp8EMjlL2u+aQqTsl1TCsEK+F1XO/2Jgv5Gy0/xBW377K6LBc2XN0zkO/5JcBfkB+8cK6+nPIu0LGYPPjJZAZDJtDHWRWljqfzUo5GKPVIEJnDfQNYlCD6A4GKCayQsxAM6wCGpO4pqhbvU1mS7ogk0bVoFPsjnbO8Z0gViCr8eQGRIqzUfNA5DTgBYc1JCgNBvrWGREwxj4AqFS8HFAoJu1vSjdqma6KiCwiCgJZzWEVaq4DLUvtjxUOdMWVLFRBjxXuh4EjBBXp40MZzWk40NqhkqpVwQjlTFWSOdkEL+MkChqLW6qyDGPiFSVQnSd3nYDg6VqWAA3cC0wa0ECMWBYgDdyIPh/Q2qR4R5n4JLJYjciiIUQwI05RMv9ohiKXlsZDgjIaq5OSOd6SyjOjYg2skKh55c1ecB/KbMCRSXyW1ghGCD8NwlkASNsKd1kahhWyRrYUggkcoLV0MQlbdQMkMq6kmkQWSpYmoGXJvsTMGTGGma6h5QqGYzBOdadzhcSklAbxr1yJbJf0uWUhZRZJdGrgMg7IGaAIk5q36dMTmgSF0VSxnIEqYp2hyKd0pBmP5VCLEb4ExZv6wlBNBPRticxYWCqai1apIpveZISwBArNaOLjV4XcjSGopVLkKJIbmryoXjhaGFPItKa/iClN77JTnPLTp+DQaSwsk4mbAtUQRj1qLoQKi+LUpadKDSRUowoNpkrCRpP/0uF/CGQgBGGJMWsa0IrCekhSTZWqRT0rWrOiVsS0NUoES050IiajVIEKXltzEniepte/vHWtk0gqYEHz1xJKQoTcqlzJUJi3vQ3nBStggIkoA1nJ+nWwpBAsZk0aCsdkp3UFjGN0lrQ+Jv0NakvCGtckoVmltnazWCxsJt/Kx1XZUbRA4+Idr5M6yvDWfLOFbWdlK9ycEhd3lGDYB4QpT0N+spqOxFdGuzbdwB63uId4LXZPYdVILMejhN2uVMUbje5CgpaeM8t1ySsI7bL3p4Jab3jf+1T6NsO8x3AvTvVr3/F29ihUwYlTAkzgAhvYJQM+sIIXzOAFd0S+2QUw/1ES3BMK68TCTZHwTjCc4QlrOCccFvCHLzxiESslxAdGcVQeDN8Wx9fFFoVwdmVMiIDi178wXguNObZjHdfixi8eBZDrm+O0CrnH7UVykjOrZADclL/IVW+RcTzcKVvCxkjGspWJvOVLPLnJXJ7vRm0K5iF7uclZ1HKVu3zmI5N5F1CusZK/zGQ2sxbNWcaznS/r5j1fGcxtlvKa69znMQd50ADVM6IPvehEv5krgIaEmX1caEZTutGbULOhMU1lS3N6FnF+4JxpbIMZW8IGKjBCDRThGFSrYNWsLuwIYj2JGKjg1rOmdSRqYAQVMAIwPRiBsEdQ6l9PtQe9LnZwG//BayP0wK2OUDYAbJ1rYy9C2gDAtrURoWxeq0DbZk0EqlU9iBGoIAaH8Ha1s33uPzPC1bCetgqA4OlLZ8IGOciAqStxBCDEoAnP5vEk+g0EJMR735LAARF0HYkMGEHYB0e4I4CQASDQO8qOqMGtVYADfW+bET1AQgyAIIN1M1wRNUCCv5EQcMMqAt8eBwDHR1DyZR8C5oOoQQwWLmlp4lwQORg5EkwebkT0+9/PpvkIcODrQgSd5hdXwRGE7e5FENzgAMiACkZwhKbb29GbiEHHJV6JDBBd1JaQAbjRLgkj5IDnApeE2V3uCKzbPBI4QPfHF0FzQdya7olwuyDy3nP/Rog95jJYdQxycPdCHL7cKoA74AXx+EL83bqMmHvQAVADGSQiB0bgPBKM7Ai1A4AISY95pkfdiRGonu2W6EETIi5nSizd63GHhNhPf/JHZEAGGdB776+NhI6roOW5h8QIRt94RWSg4hmgffIDz3iZ437viXD9IHiufewXovvbh/YhwD+I4PM5EbJf9dx5b4ga5AAHzzZCBo5g/krg5fZ+FzkOLv71TmOC/LBXCUw3fBlHctIXgI1gAxnwbJKHVG+1ap3Hf9PHd4kHAANIgJknfBi3CD3Qbzlges13CCGXAx94fRuYfTHHfa83gYQAgA3ofYIAgDGwgkWXCBe4fgs3/4P1F2wVJ3Pw1wM1d34oZ4AAAHpGIAMaGGN+xggAuGSWgAM4cIKRcHksqAgqAHwZQAQ06ISUQIVViAjd14Sk01bLV4OLIHgAAARHMHnZZwP7V3hMGHNNEINrCIPl9novKIUxqHoxIAPIJ36IAIWDMHWCMIdgqG+X54WAyAi3ZgOeBwCyB3abpgli2BuCqIeLUAOwVn9fyAh5iICOkGs9iIGJMHsyV30601acaIeGMIOCYARRGILixnxmiIKDSG+gJ4t7WAifmIqHOAh9+IeLWAiX+IqMp4aGkGscl23MN4qYh3KbGAM1AHDMKIn1Vgkf2AQZgG20MQJa+HxJWHu7Bv98MoCKnbgIvehkb3UEMlCOrMhtwHcEwjiGkVCGtagIHzh/80h2Njh/a+eLi5CN25htWLiP9IgIAllqM6iF4QiQTicD2lhqRICF5giHyfiN5tcDzweChMCOMiCPlAd8FTmM7UeO1deHz/eP9sd6pXBRk7aSleZ/Mrl6MXmNNNmSkQaTgjaJS3hnPamLSsiT1jiURFmU/SeUP5aTbHiThPaTSxlmNgmVRhmUn8aUSBmVC5WUTkmSU0l6XemVXymVRzmWZEmVNamVO4mVVnmVZlmWYDmTawmXbamWgdaUuBBqXCgoJUZiSKFiNOGXMQGYMyGYMEGYgbmXNWGYhYmYNqH/mC/hmIfZYCABmRM2Z4zZYR42FJSZEpu5Ep2JEp/JmZcpE6EJmqM5mKcZmUlRmpmpYFZRlW75lnJZdbBJm2wpm7OJm7E5l2gJaixpl7cplroZl8S5mzpZm8JZnGHJWb65lRaJnMeZm3W5nLZJndEZnMkpnVTSm3Q5nMrpndVpnT7pnJj4nbxpnNmZlWkpnuHJnlwJnunZnuj5jNApn+Z5n8wpZt0Zn/x5nfhpn/3pn/NJn/UphOR5lttZoAB6ngw6nfs5ngr6nv+5oAHqoLaAl+p4oEDZoBX6nNcYBB7hBILAAU8gCE9QogAAogEgog6IoBzaoQT6oBSan+qJnS8K/6MeOqEG2l4H4AQckARYIQA/sGRO8ANO4ARA2qIaeo44KqE3Cp80Cgsv+aQzKqBQGp5BsASEMAQAIAAB4AMZegA/IQhcepARmqPaWaVW6p6pgKFTeqVqGqM6KqcBEAWGIABDMKRaEQA/4ANBwKQWOqAQeqZoKqOq4Ka/6aJz6qRxSqeAJABO5gNd4QNJ8ANS8KdmaqNrSqWbCqeBup5SmqhL6pCG+pRz6QNMcKcAkKdk4QMHoKSEaqqeuqNp+qnNCaqCSqu1Oqi5mqNDIAVj+gQiCqlOtgRY4QNlCgVJAKuaqquLyqtsKqfcWaOlKq27yqidKpZBwAQ/YBQ/Qay/iv8VULAEB/ADSVCm4hirG9qkhfqs1nqr8Fqt0Bqtspqttsqu9dqo83qt2Mqp56OU66qvzuqu+fqu/tquB4uws2qwCzuw1Pqw/MqwDXuPCauwAmuxF0uxEaux9Ppo8dqxGHuv+EqKFRuwGWuy9iqyI8ux+gmxvbqva5GajymzLMGaJmGzI4GzJKGzIsGzPUuzM9uafQm0T+Gzgymq6lobArC0TNu0Tvu0UBu1Uju1VFu1Vnu1WJu1Wru1XNu1Xvu1YBu2Ysu0OiAABHC2Zou2Z0sAacu2a9u2cPu2cqu2dOu2dRu3dzu3dru3eMu3etu3gPu3gpu3d6sDSNus9je2irv/uIzbuI77uJAbuZILtgQwAAIwAJh7uZmLuZbLuZrbuZsbuqA7up9bup57uqJruqmLuqTLuqrbuqsbu7A7u6/rpaNKshY1ubq7u7zbu777u8BbtZVLu65bvLJbu8ZLvMebvMi7vM6rvNCruQRwuPJKKsF7vdibvdq7vdzLvN77vM0bvd8rvuA7vuF7vqc7vbdLqmHBve77vvAbv/JrtWxrvvZbvvhLvvqLvvnLv6SrvknLsrk7vwRcwAZ8wLpbuf67wPe7vw3MwP37wK5LvSCbSQh8wRicwRpMvxHcwQ7swRD8wSLcvACMuCertBucwiq8wgU8uH5LuC8cw4ELwzMs/8MuXMM4fMM6nLeGu76A6mVE65lBbJpCy5eaOcSiWcQ8YbSTicQ168RDu2CvacIpe8LlqbJY7LAri7tbfMUTC7MtG6o+zI8VzMVanMUSi8ZpbMXv+MX9mqAfu7FvzMbsS7AFu8ZVjMdnrMZ6TMcBLMdtbMd33McC3MVk/LIou8d+/MOGTMWK2shmzMdzPMmEXMiSHLJ5rMiavMjV28leLMiJDMaczKyAHMijnKmOjMmXPFPTWsqDvMmUbMmnnJeeHMmZXMmqPMug7Mp1nMq5HMuvLMq6TMu83MvFzMirzF0Aa8q3DMvCPMuaVsa2jMuyPMwZipNwtsyfbM2gKM3I/P/LwEx3YwoAJ+rGzNzM4VzNyeyxYYzI4JzOoazO1Lx3xHrNj8ABr4rKx3zI7nzO64zNuLrL8fzM6OzP87yB9dwVQXGuAMABTHAADM0BHOADkmqs42zPtTzNzvzOBL0u2qzR8MzR8hzSxizQEuelHmEVUYAVTvCqQVCiyupkUhAFFP0DJJquGV3SJv3NBc3OLrvTIN3RB63T5nxyAiDRP4oVUvARkDoEUMCtr9oV+EzK+0zV3szTG63MrdzPwSzUXj3SJE2qCR2kSP0TPwAFQzDVUp3POH3V/AzUVp3TvjzXBt3TXQ3WAy3SCI12BwAFgvCneAoArnrNHDCk+szVQR3/1on91W360UT9z3it19s81JNNoGO9qtz6A6nqA+SaBFFdJUYBpt0M14dd1aXt1qgN2Yut2Ktd13cd2a4t2a0d27I926/t02L8x3ld21i927dd2Vnt28I93MDNzaqN2L3N2Kz91tacZopG17QN28Q93bpN2qOd2qdd1Mn927bd3dtN3Y993NEN0HGM3MVdyQ9GxBsGxVXB3jvr3kUB3zn73NX93dINnLkN3dzt2gHAwr1btjtswzQc4Dk84Grbw2Pc1tgd1+UNx3Lt3eGNVP7NuwoswSBs4dFbwvp93ssN4Q8Oydlt3ljd3xOewBd+4iPMvPS94REO4qY9zHT2yBxT/+K7i+EhfOP3q+EfzuAl2+ELHtzjfd/8TeOTW78ojuNHnr4rvuMKzuJOrt0tLt5R/kBELrkVnuRYPsI6/uPE/OI8/tMeneAh3rAkXuWPO7xInuJZXrpLzuUxvlSObd8ePuWVXOZm7rgEnucGLuB8PsMIXt9yPueBDuguft1ebuiJkN7tvcTynbON3sRKDGJtfugYLeZQbt1dzuRNbt3RTOlvatfgzdyY3uOaXumE/uVSvumY3umeXmaTzuWFDuqCHuanbupezuoijuqxnumwnuq73hsSgADCjgASkN9MjuukHuSzjuiXPugczsoB3eMVUADUDgETMAkGgACj7kDI3v/sot7cri7jyS7u0K7fCGABD3AB2g4ACHAB7D4BE1AAEQAAEUABBlAB9G4BFFAAAPAA9s7vQP7syr7s3e7tuu7rYz7ulq7c3B0BFlDsF2AAgmAAFxABEBABDwAB2m4BCPAAE1ABGR8C2q7xAOABAM/woc7sCM/rCu/s377yKm/wlI7y453x+C4IFhABDg8AIeABE0/sEv/uAJDtACABFkDt9h7ws17wMM/yu27rrY7bW+3gIEsBFEAIIUABHhACAEDtP48AQQ/2Q6/tCKDxwl7slE3n+03wry7zql7WmKr0y57wVG/sHVsBEFAID2AB6A4AES8IJL8DD9D1XE/x/b7/A2iP9jQv8Iyf8jEv62rfrij9peAu9dEeW1spABBgAJzv8wCg9YPgARBAARzv9xAw+oN/AZtf9JsPASfv46re9FDv9o+f9iVdz4Lgqq/pp1DAAds6xbFP+3RP6w3e8oOQ84Mw+ACA/OQu9wcP+S8P/dHvrJMPphzApUwApgdg0Zfq1NNv+42P31Eq4hVw9cdvABBw880P/sEf60wv+25x1BL9p08QFMYKAGIqCEsQBdcPCACCgwABAYSIiYqLiIaMj5CLjpGUlZaEk5eam5mblJ2eoaKRoKOKpaaDqKmYh6ynrq+wsrO0iasAAoRPS06FhwccgkNQTFJDt7G2qsrL/63OtLjQpM220tPT16baodyj3p7g3dXR5OWMuoMcP4JJwMIA8D/wz9ji3+bYmvf6v/b5kSR4APBAgiIJDwh5MIgQGr9LDz8BZBVRor6KFv+hO8AxCoAkPw4weSeIyY8fHpNdnCgLYz9/Ly25hFQRgQEAAhUtJGQAAYCdzmY+ElorG0tRRBklLerw6DanSKE+jRmVaqWlKjU9KGBgws0IFbYOKvCgQgQACCZMsODTLIACFwxQELTVgIcK4zQGlRqOL0S/+wDLFDy4H9ashgnHPDzV6CYPBQBUuGkTgAWGFgD0jAAhwgMIPnvmwjsBL2TJN/vqXca43t6Vq5smhv2ydf9Lxa8da9qRsHLlEHMp4O0ZYqDm0D7TFYjMG21qTrhpRpc0fWh1prllx9aue7ZV6N+pbaeUzvfNBxbQJ+y5XJBo0cojl38eePwr24Js44fJvb9/1tdJF159AyoVIGKWgAZAXM4JQoFc7iHAIAAKwidIewpOSNZf43FgyIcghihiiByNaOKJKAZQYoosnrhiizCK+GKMNM5IY4w23ghjjjqmyGOPLP4oIj3f7Qded5ZIAMEEDzaIkwBnHfcTBBRUmNyFkSmp1k0SZMYhkvkJIOaYZJZp5plopqnmmmy26eabcMYp55x01ikAAXjemSeeBOjZJ59+BgrooHsW+qehgiL/SuihjCba6KJ36nBgYQVSZ1+BCUk2VwghEPhfAHaGKuqopJZq6qml9jnAqgKsOkCrrLoK66uy1hrrrbTiOuuutubqK6+69grsrwRMepWx+Fw6YAUWGGBAQht++Smq1FZr7bXYZkvAr8J2G+y33II77LjehmvursiKVyl21qQ7IH6lgJrtvPTWa6+9255bLrni7utvvwDrO0CxBRrpaXbr3jaevPc27PDDEL/5r8AU81vxxBZnPLC71iWMIICLRBClJUCx4tOR00as8sos46txwC9fDDPGGBP8LscoI0xIBXhdIlokPyfyM32Uptzy0UgnHeq2MTdN88xQy/wrzpZ6/+yazoMg0NYFatXV6VtxGSeaB85ecGFcc0VgAQWRTWZAZGqz/ZYgk1EQJVwQftzuLUr37fffaeqg6OCPEu7o4ZAmbrjihRcuacFUS4s1lpp58EAIoKF3lgBmT9CpaGZrPhoApX0Wgk8IJFQ6BKfnItkEDyDgpQCk9Xw1yIh4CCSIQu5O4gG++wh88MITj2LvxiOf/PDGm6h8888HQKRVBkuOeyLtiVaZlPNJiQDZO1z5VmQ/R8CVBeSfrMsEJxtgUHx6nzO5/PMrDOb19+9dW+RVWc3MpdlDXWos1KCeXAACBiFgAAGgNrMt0HVDE197GuGu1uxHPxyDVwZxdsHIVf+vf/7jz/wWuD0CeuBzCCjAQD4jQfKZDQEQcJALBaGL4hBkdpSjoLIak7/7bHCHFOHgD/cXwqqFUIOLIOEAk2MAKq0ndRDoioLgd8CbVKkrkami6x5QJQiYzXXji5/98Fe/VHQQiGYUIm28U0QdFhGJoUjHGyuIrDP+R393pF8Px7jGNv5vjmhEhx/hSMZC8rGMaexjHg+5R/998FiB9KOBIpkzRCaLkqrBZF40CUJJitBqhPTkwQwZREXq0ZKXbKQPTblIR/IPkqpkBNHeYgDbyeJkGWllKnW5S1R20pe9JKUwXdnGUF5CjnSbAEFeMbSiAXOUw+QhL4OJx1hKk5P/RXplLhGWFrn05gIPOlndkKmZt0UgLeyjmwROJ6EHSQBtdHMW3NYWmcigxm5ny9snq3nKaFKznwANqEBXSURR7jNhoZTAWYBDywh0aUGwiwA5KUABBHRJZBY4iwHQl0IDOHQHtUOL6sLCuitVAHayo2FID8pIglpzky+F6TSv6U+XevKR28Tf5SYQxTC6bgJfJGd7QmDPAqAwh/Az30bTR0PSte99OTRmSwdKU35a9apYnWpN14VTdfWHdbG7yQR18TOh1rOoTPVpfBoYxrJKiXtRpeNMf0nVRMZUpnPF611vVky5DkIACZmMWn8SmQeYFScx1EwCTzZWLMFQhpoJ/yoAbIiepvpUqjZ9JjSzWkpsbraumR2kNr2KMGbJRaz21MUD5HnYt0AAAvb8WWPDeMUJZLGnqu2iZC/r163SVauhBS01OUBcDgTBrnv9LSCXm1eD5qe3nO2sZisZXeQSQgAf8oF1p6vXvno3uQbFrHSbaz3fZjJ/yAyCdgHwBCgAYAhJAF5+RHJcMQJXuJXqqoDAK0rxbte8n71vVQGKXUP4YAjHKIRH5gGAKASgGAAIgi/sG1zuUm+0+yVveKGL3+5WWMD/bKkAinvcJGh3CU8IwhIMEV8f/MAH9aXweD1LFf127K4S8ApPENGQWUJCZP/tcHmrq1wQFzm45FSxE/+YEI95EPe4HIjCitlF5BmL9rt5vUymLDuInZAzEjwLspGpW+XzatiZk/vyAZYgDATXNwhBQIYTDkBlIR8ZlBi+cSvRiToBFMCWtLML3TbHwAdNwCBg4UoFcjyBs2hNMlxrNFq8QoHeICDMMh6wmMdMZjsPmcAcOUBKXDyIIITkBwFwwqljfDsA39ljNp7kHtWGUZEJwKLX9Ynn4OpQnGRGdqlD3+Xmkj3LMVShkyX2Du5S5w9r2tnPtrKnP50IE3uY0yEmJnPrR9QLderL3SNgBR6kixIKsK3n3mlPJ9hsabsb29SGdrQ3vYslvHre8kZonmW9yAm2B9yCqIyFPID/z3IvsUFKpFAIwurTdtM72+9+uMQhPnF8UzzfXN23EeunJPdAFRHpOCFcDWA2iTpJe6j13k0Ai5qGZ/riZrZwTl0d74hj/N42h7XGHf7sArw2tYkQQBMrDdcu2cXgEUI4Uytj2iax++U47zS80Uxzqpc56te+Ol+3XfWbctgSunMR85ono7GT3RDR213ae7R2tpv97B9qu47kDiS6w714d/edfPnrdc8yDHCAr5PgELe4wjeO8IdnHOIXr/jGG57xj3d84iNP+clbHvKXfxzfJelfmgT+83TKl9OiNnqplf70TzN96lFP+tW7vvXi+rpzM2zhv4P+9m16vephv/ve/7Pe97r/vfCDT3yA2ezMl8A0G2uP++azSVW8H370iw/86Vu/+tiXfva7dXyZW+LpNJ75VZxPfjQxjfraTz/613999bef/dnvftfjcmgGVkDRjD5LASjqPvun8AInIyH3NDI1Z3F8U34IOCaiB3/ut33v94AOGIENOIH7InuUwDUPoDaxwxboQRYMVQCwIwE7gBY7YFsTQnIntYExp3WqkIAuSIEQCIMSyIA0GIM1WH3yx4KCwCTLwRbmpnQRsj2WgVFO5XFSl3OS8IIIqAOY14SS54SVB4WX94RUGIVVOIVWmIVYuIWConlnZgDslDo/WBkT1BNCCBwiF0FHWHGJEP92zvN2cGd3LSKHOwKHZEeHc2iHZ4eHQaKHceiHeTd3gBiIx2OBkQCCdHFOB0eGhTWCQoge6TFZK+QlAYaEK6iDsLR5pOV9mYh8lYhnWCZzHhBFnTGGYtUsXuQkDmIcXPRaX/SJBgiLsSiLMJd1lliLtjh1FxaKXScLGXVzl3iLuYh1wQiMxaiLVseJyweKmpgK44aM4ieMxziLa0iNtIiL0wiNBXVEhjh7PIeNyaiNeuaJm9iLnaiM53hlXIeJ1ciG2TiM4BiOxniN8BiPBTiP2cSL7EiP9fiO/kiM92iP6biPAzlt7Zhx+miQ/PiPDBmQACmP0riQEjmRECmOrIT/kM1YkApZjvjokAf5kBVpjRSpkQS5jDoXfh7Zjx85ktEYkSxJe+gIk+YYkhjJjShJkwLZkiKJkyvZkC8pkzMJlDGZkRsplEFplC6pk0mplO7Yk075lCkJkjW2c1CnklLJk1DJkUXJb+SIlEuJlVn5kzdZkuM4ll65k2eJlmmZk8xollzpll1Jlm9JlGUpl1VplWAplvmlRnBZlwlZk0O5lmwpmHq5cXZpmAUxCED2CmHWEIyQEyTZkXnpk/m4jlvJlE1ZmK12mG4EJkIIfqPQHiWjCEKolZc5l3HZl5kZlXipmZ3JmXfpmq+piu1RAZH2Te4kCPSHaBWQQoRQm/oX/zZcpD2wVUsX0hUGMZuB+Y1fuY3alpqmaZGo2ZzRqZab+JnkMxAhoExcURAjiIEaiAAlaE+UAx+k0WgPJTuecRnbiROv+EeqqZzQOZ/U6ZfLyZytWZ2rGZnbhZ1vpQtlmBZsUwA+OEsLBD+usz3LUQEQsGj4eZWYWZ/xOZj2eZQVKqGxGZaEGXP+6VYBCoZaI4YGylQIinRh9D3ok6Eaqp+SuRhUKZ/SyaLWeaEUSqM1+pbqIQhWAlFh9AAjiIgEoYjYQ6JI5SQI1BATspmwCaMWSp/7yZ8tCqUQOp0xqqLlVUWw5R5R1H8E2kRfNIpNJKSIcKBFKp5NdFtNlJxKev+ahkmXTjqjVLqkTIqhc0qndTpxQeNygPmmayqnVWqndxqlEZqfG7qicYqEeQqakGOSfhqoe3qSbmqjTzqostmncHqol9qmTfqgN8qnUyqpgGqlUmqooEqZrDmZqJqqlNqp95mpolqpluqq8OmpduSpz8WobFqqi2qZf4qpkyqjpOqrhLqqsHqrF9mrmsqrezmhrzqqpgqsw6qrz0qsxWqskSqsy6qsocqp0wqt6tCHhIh2g6h246p35Vp3Q8Ss1nqsz9mum4qtnwqvLaiEa3KFUniviueFtrqurcqtlWmT15qsueqojUCvagJ9M2iDupKuARurgsquW7evs2qrD2H/ewZLJuensAmbKznYqPz6rgLrrpAqsR8LshM7fhd7JguosRTYsQPbrN4arw0rs/7ardSalxabsmJygzJ4Jwy7r9UTa87qnCYLszHLmjmbsgjbswz4s/16siTLqr9aqNF6tDirs2aSsRsLgy6LrARbtTc7lX/5sGGrqlSbtBcrOFxor2y7OPr6tFD7sjUrtto6tUNrs9IqCG74huGqIucqiH3Lh4UIsdsat0VLtl5bsnCruIj7tXgbsoXLUolruI2bt/8qsnJrtFRrtpBrt50rqw4rtZorrzS7uME6t9Uqudtaq4erup5LuqeLuqdKtwAbtUbSeaIbuo8Lu5xrudUa/7Qv6rsz67qTy7ir67TFi7uvy7u9a7W0i7nFS7mV67jN+7lgy7xlm73au7mx27rdq7ugS72zy713W72yS77bi77Om7rhW7riu7vYu77CW770a77va7+ja73La7rFCry4Or3GW7is27q3i7z8m7vuC74ILL3hO8CZG8DtC8H7m7/zS7Qje8AFPKEOHL3eqL7y+8H166JjG7kKDL8UzMDtK7QdnMHqWsKX25YYzJd8usHTi0u20JhbdhDGAcD3G8Lja8H61sIoHMEWZMCA+mWvIJpqSpo+lsA9nL4gLMT960Ey3K80fMSEUBcb4ha49mi76X/kGUZugTeWE05oUZw9w/8V9fe9TxzFbhy1+DvEE3zCLgzF+tu9yCQ3+9dWc2FAEZUe4mlbv0mi5+lQv5ZR6LFOyvROJny+HmzHBxzHEkzCxJu7VzzByDSCguCIHlUlADCCPEigWjOicDVYCvpnDbrEPwzJdOzIUrzKFSzJctzIk+zElawJyCRH6bADIXABHsAgIKo1DDemRGrKqdEeKBrGslzL1/vIw0vLs7zAzMzGlyyryARUk7aDXJKlQJqBpVmeLdRU23OkCZGksOzMdyzNc7zA/ku4lmzEmOwstSQB8pycDGUZJwOmpUjKCgR0ZpqlWKrKPszKbTzQ7ryLzxzN0DzNy4xBHfyoBEzFzqX/wq3M0M2czpVazer80PFL0HXMxhx8zhh90a480h6t0A3djZSs0Twc0rLczupaxAe90Bad0v/b0gX9yi8t0TMNzSxN0jlt0st8y7Yc1HBs0B2N1LG81HrLO3/rdoQouMfz1DfCI9Ojzj+9zi6t1CWNzkINxWiLtXLChG27torytlgNzw9MyVMswj0drGEt1nCitUyrK10L0igt0l7tvW0NxI2aFHEt126ysltbgdGb1RHM1npd0Ub91W4c2IKdeyz7L3eduoi90Zi9024d09cB2ZF9sHWtL5W92F1d2kmt01zN2B+t2ffx2XZC1zwrLKM91Jdd1IrN2jeN04Dt2nVC/9ihjS6HrdZbTdM0DdPDu9u8HXpaiK+Fgta2TdRAbdoei9fGTbHX4YZSLXZRTdVVzd04AodX/dy1Hd3D/caqndekvdpMfdrSrd573djtjd7sm9mpDd+OfdLQnd7uzd73vd79/d77jd+3Xd8Bbt7xnd82DbQqrdXyLeANntvhobw4XdMEjuCwOt4J3sLVrY61G8MQ/s5vrd8P7t8HTuEVft6JTd08zdkK/swSntYhTt4TruKbfdx1JNy2/eLijeMDTtw07tcPLNPMiuEnbuJFbuE+nuJ9/eFEfOMxfuQ6LuNGbuD/ndBL/uQijuRUXuCqHeU+TuTz/dxXLsRenuERrf/hVezhGzbCDM7lVd7eYA7gI87fJa7lRz7nVp7lG364Qj6zcS7nU77leA7oPS7odp7lgU7ngx7ff07i593oDq7ker7iNt7iln7pLk7pnBe8i27fdV7mUJ4uq2DDi/njCQ3phl7ogL7nf+3kQ24OyKR8Y+69qE7obW7qWI7bHuvQioBMj2abXVPktf7mdZ7oea7rZL7gUs7rQTfIlTNZyoTfw17irN7hMMzXhy7tru7nsO7sbqXtuR7qNb7pbC7pLDzDPB6MyPRASHzg097lms7h0Dvjxq7obt7pns5S685UXCPs6Z7j8V7uLzzd9U7snv7uiit0znJ/5LOlAm3w957/7/ge8cVO3+AO5JPb57QqFXl68af+7xaP18Ud8K2O6VfX8YaO8BQ/8Sge8qtO8kG+7Rsf7oR+7rbL6RDPzjCf8TL/tCqf7bb+8ytP75M+7nCr8T4P8r+b5thO0bY+6xIL6uK3t+Ya1UqP6Dav5v2F80Bv75+u7Jfo2fSitoni3DFP86le7fO+qzfP5NGNCmJPL9x39WZu8scu5bie7BpMDnGvLeMy2zqP9jW/89d+wU3P9HIL90gD26xC9+Iu+F7f8mJe9Biv2z0fJkfj26sC+EUt9F0f+RKv6o4+9KT/+XDO90kz95BP7Yi/1ixP9Mj+8Xt/Cov/944v4Fl/+BPN//VSL/Km38qKfzSDBym3n/atH9JOP/qBX/mRi/RNDT3ePYfFP/huj/cFj+2xH/VgL/LMbt2rn/OvX/qSnv2m2/vUb/drnfsE//vY7+9Gz+eX76c/7/mef/3rT/60vv1Ln+loDggAgoOEhYaHiAEBiIyNiYuOkZIAipOWl5OVmJuYmpySnp+WoaKOpKWHp6iDqquEra6wrpSQs4aysbW2t7q7rL2+r8DBqLjEpsO2xrPLxcnMz87Hv9PNotac2NnR0NOC2tfc3pni47ze4J/pneXhx+uj7dvj8KDy6vf49Pnu5qX1xAAi80fLnMBGB1PxY1dt4aWEj/YZdBiPIMR3FP8xosv4kKO9jRpBhmwokqTEkicJzlP50eTEly59XVQYM6BHhDdxwmRZk2dLn4xmFhIaMaXNkUhl5gy6lCbKpECVNT0atSjUq0qfSjWaVesuosJ2fkJA9sEhCR5Ugt1a1SnWYGup9ezmle5ctne/chRQoIAFCYYQGDjUF+5Uw23dUhX7Nldjx49XxY1bkOsmAYIuGIhAwcAEwIIBIJhggIJZAwYKRABQoLTZf4e7Jg6bV3ZtybEr34ZtWW9v25wwA6gwIQJgCRZED5awOgQFABQoIHjgoQAAzdJm69QuN7Ld3bwXe9dX97v48Yz4evg7vDPm0A9CTIAwuDCAHX0LCO//x12x9sm5nfObeXihtwllAA5YYHBkCeIBBau9NxgEITwQmn0CkNVgeP0J2F+C/lCm23kLImbgSiceGGB3n+wHgAEXABCBhAAIYFYF9aX1YgiCAMZhh7R9uKKI36xYZHnZgUeekkumqCIqLiJngAc0VmBBaYNFQJ8ED8wHwQRJAsnif0MaOSaJvqGZppolrukkQ2I2GSeRHSHp5pvk4Jmnnj+xSaCJcT4Z6JEdgsiYn7jxGclaCJap4J93MhkVnRVJ+qOi2wGKqVWbcoooZJbyFyile3Y60KNhRgqcqqxC2uaqsH6aGKl9amonqLKiaOpQRhq6q3+2hsoTrYs6GqKZ/7626mqit14a7LPKRjsbsaf+6mmucr6qrSUcKOKttwcc8O245JZr7rjhnqvuut+my+6757oL77zoikvvvQHIi++94g5KqJDN4mrtmcsKnI0ACCes8MIMN+zwwxBHLLHCBFQsQMUEXGwxxhpnzPHHG4fsscgdlwzyyCibTPLJKqfM8ssrx+wyyWamOq2xh0JbsKjYBjXxz0AHLTTDGQ9gtABGD4D00UkvrXTTUDMt9dNTO2111FRnfXXVWG+tdddgcy3211ITULOzs+KMKrMDNyrZ0HDHLXfCBJBtt9d4h3233nmP3ffefvMtONdm+zsimQGzLWylOu+86NyQRy5x3f+AV/735YNbnjnmgXeu+dGF+0ttpj2jHavjupaeiuSst67w5rB7zvnntM9ue+xan83zzYnb3Lji0vreievER1607LjfjvzytSfvfNm6Z5t276YHvzvq1w9f/PZw161888x/L/7z4O8d+qCjM0V99tZLb/Dpo3Avf9A6yNzy/TDPrD/+9ufP//7+C2D/SKaD6KWOd4sT1PrqpDo4laJb5dLXvtglwQnGy14WpCAGM7iuCnKQXB78YAQNqEDuJCuBjGtgrX5XPewdEH4ufKEK1ULCas3QgSgs1sAIFsMSslB47XPfD9uSvmsFsYU9ZOAQ2Qe8JcpwW0lU4tqIWEPSORH/ie+DIhOzyMUolmqHPNSiFy1SRfXlMIVgBIvbwHg4GDbxij484xRpuMAninGLeATiG4+Iwxt+0Y9oFFMRgcVHId7RkFjUoyL3OMYVwrGPcqxjJI0ISB1OkldzjKMbE8nJTiLykJMqIyUbGchHlrKLqPSkHRlJSkte0oqCFCUhQanKVS7yk7fEZS2lWEkb9tKVo5Klh37pS2IOs5C8ROYpWwlLUy5zk1QE0gnZ2EZlFhOatsylLvOozW12EyiDPCY2v5lNbmrSmtdEZzppWU5zknNYwsTkK80oSUem8p1/dKY92XlOfrYzlNJUWz3zqc5RMnOW/iRoQdd5UIYirlAC/52nOBc6UYpWNKH7bKhB78nRqoRTntT8l0TDiM9nllShGr0oRjNqUWOy8qUrZelJm9nSIKWxV8jCKRkN91Gb6jOZP3WoO/8JyXEqUEMausRgNtpRb+6SJT0lKUxTqtKpErWfVh2qA/uCGvs0Yj8uAulIpRrTTB5roCZtKlafmlatFnVB9pEAaWIEALnCSDR8qUCNNPMcsbKRTlFlKjzRitKy0tOoa2VrYYFXGC1F4AEGQIBjISvZDAFGAHqdgF596lK/jpWqigUmYYUa2sN2VqSnRW1hQpCa1hSAtVy1DlgF4VXUpta2IS0tYoF6W9watqpZTexMfVmYAkiHLBEwrv+GIjQI4dS2mrvlbVDNmrPfkna4NA3uVduqW9MWBgEWeI0EwCveGr3Gudbh7HSzG106QnS0or2tGnX6V4HapwL0gUCM8GsA/bIGAmlBr2fXa9rPqrW6oAWudt+6YAY3WLoHdnCCfUvg3HLXqW6VMHYRmuA11hfBE1bve0ecWxFNM8IQ3nCBazrg9i7Wur0VboZl3F3BbjfFNbYxhjX84Aur2MIvzjF7Jzxf6vr4xkEWModRTGOAkjjGFIZxi3ucZCRX2coypXKWmbzTJ1d4yFyOb4gPAsF6iVBdITxzmtW8wTODsM1uBhec49yuOdOZg2u+87v6ZWCyavm6TcbyN+b/R2iJ6eB/iBYgAAe46EYnmtGPdrSiI03pSVsa0pd2WQHhC+gZbznQoF5doUfdMO+Rb3zhO7WqU83q8qHa1auu3fmgDF0W+1nQnfYZqXdNt1a/+texBravg03sYRvbchGl5on/nOtE8PrZwob1saNN7WJL+9rVNvasv7xiF4s5zN/WHrRHfTxsWzvb5p72udetbnVv29tHxnW3mQ1mUIyb1KZud7r3je5+s5vf/77cu22t4B8XPNQ4tve9C005f+vb4QB/eMAn/vBkx3jZBj84QhZObkx7XNIfr3TIMy1ykJu85Cgnucpjtuk+R5nIufHwAyNoZzfnGc81Z7Oezbxz/0XcXOc9F+HPgw5Ci3Nb4wgPd4fp+2EjJxzcTv8sYHPKaRFL+daeVjrUm83jrbv86TuWd72zPu+lR/3TYQd72rvu0Xha3etcZ7vYp2z2qtMd7jpeu9rB6Xasz33sSn574AU/eL8n/cp61/rVCZ54wGcc6XLf++HjHm/JR/7vkG+83R9veLIrfvAyhzfl0Y75zFu+9IxH/csXT3jQM/3orfe84zVf9tTTm/W1Fv3oP6/61cu+9pzv/OR5f3sgk/7ytAe+68++e+L3PvdjPltgl+wTjNve+r/PO/JPj/jhO//5wodq332f/dn3vsibJ3/571587Xv/+IP1su6/f/6Yv/9+/u7nfvffr3y8w379sdd+1Ld86Qd9AhiAyZd/+reAIMZ3Bch+Bxh+9Ld98MeA5keBlWeBFeheAPN1JmZ0wad+/KeA+6eBF2iCzcd8/2eAIcaCAOiCLwiDCQiBhSeBJTiCtJaBN4iBOziBG9iDJ6iDPziERJiCRfiA9ddlD4h+YxV6+DeAISiDNeh/ITh1Dch5Toh7UsiDPoiCUBiBWoiDNAiGNtiFRth/z4d9UbiFXAiEKviEY7iGapiGAZKFWviBb3iEXyeEZuiFX4h6dkiFCCiGcTiDhRiDLdiGaCiHIDiFjHJ/cHiIhDiIiCiIiGiFeUiCZ6iJm/iHk1iGemj/OCY0fmzIh6bYh50IiqmoikEYip4odkjlI8SAFqgQAavRCB4AGpFYg5i4hPaXiaZ3iosIfhDBF32xWYUQWasQGqVQAXqljIegjEsVhorIicLYiqhojasogkmIhKV4CFHCI3UVAhFgARRgHQ/QGelVARIQAmRxAZ2BADLSGZ+hHIUwGhOgGgCQjqkhCBVwARNQHKIhWeZoHTjSjy8ij9bBGZ4hi4bIi9JHdSMViGT4ja4YjNdojAWQWQXwADvAJRQijxAgj9XxIhZQAAjQGsaRHMZRV8nBjIIwWSMJADNZklMSH8/RFw8QkqJhFpqVkDUiI8eRHFP4iRbphxiZja9Y/41JqZTaiI16mCFkARg7CQGbpYzI0RedAZSskV7CUQHuYY+DEAI6EllZaVyDoYwXYh3QmFwGcJJA+ZVhWZRM2ZTyZ2sUGYVzWIlHSQhhBQAesAOvoZYjOZVciSGACSFBCZNdKQiRhQCFiQCAoZb1wZbyWI4xUhjKiBkPwlx0iZSsOIrpl5eO2IgV2ZfNVQgXoF8Q4Jgx4pE+Mpny2JhBeVczIpaZsVQjCZs9ApRr+SIxApmCcI5xCZwy8pd1SYakIFkxeYuiGJpLeZGS6IZQWZ3WeZ0CgBpTghyrER3XQR91lV+WSVte6ZJTQiOE4AEQQAEWII8SIJ6+WZnfORgUQP8f+VicUkIla5icPiUArUmbjACNSjWbK8iEO0SapXmFovgaFuCcwRRQT5FXjfkArvUaMVmQdTVXtJVcEXCQC4mh+DibDImStOUaogGPAkqJoImgDwmddnmdwxgnV2KVojh9yWIjrVkYxGlchLCT7jhZm5kaETAdAKBZPkqQttigNCmPxFmS2KGSyBGd1PmiMXqNT3mlWJqlzxlNd7kgmLGRhbEDgyCmhKCMsOVaQRmTrQGXZpper/We5Hkf+fGl5UmlUrqNLqqioMmNRsmn/HmnZ9Wl5oEZO1kYs1WmCnlczCkcmNmYymgffcGMhopUtImce/mneZqpejqlWmqngGr/pTnIqcfkXHA5AcEJJmUanOHVm8IhnNDBljECpy/CJYIJmGwpjoCBmJ46nU7ZqX66p6gJo76qqbu6i5fYC8LhkdYhAdrpkPM5HPkVI/tRn55hHatZHxAAAev4Jf3YJdkKJrrKq9IZrFUqqsVKrL8KrOSKp4kIrIH1GhSAjO76iwXIoi2arqB6rvrarvm6qcRQnwB2rwaaWuBQZnuWcx80dBaksAuLsAnrsEBHdBnEsBKbL6a5pfjaq/46rlsYABx3b/VzcisnsiNXsiR7silnsilLsi1nfMB4rvYKah77seNGcRF3sxCXszaLOQMnZZrhAfzorL7YdKozszTLa+Wm/7MSt7Q4u7NOWzU9q1Hl+ADpyCMWigjIKbD02oT8YLRHi29Ny7RKG7ZkO7Z4c7GOoBn16BcbiaFq6yNqewEIIKHKubUH2rVfi7Ri+7Rly7dmW2xRG2YA+QBTi1+SGZKDO7WrSbgVMCOSaYnrurEaS4lem7eF5reYu7ea27fuhraMMAHn6BdksVTKCLp90Z6m6pe4N7D/Bw6Va7nyk7SZy7m0+7ebazuBq2UG4I5lwYzSyLvTkaJZ240rGLmUC7ujVj8ru7wjy7wq27zQ+7zSuz+eiwgFgKqE67sKib3J1VeXdbUQSbRwZLAaFHQUiy/ni74QO7Hr+7AVy77vOy98pv8o6tlfQ0q6s1m/EPBY1GodBRCwdSu+xpqx7Gq8+2rAn/qyAYyxkyu5w0rA5dqv6IrADiysEayEormHgdo2kHiH1UuMHRyq4IepFCyu5lrBB/yICozCDwzBFtzCp0nCvSh1dkuwIRx9CvqZ03fARjnDNyXAqXepILzCCeyNMhyROfyQMUvCJbzEdIjBc0KKQsyXU3zCLGzCDTzBeGjEJQy5xEvEV4zFLazCQ+uNTnyvXtzDSAzGCHzGVoyubqyuPhxLEOqBEsnBYBzHHOvCLxzGMLyf8wrF8lXDrXvDXrzFdsxTUvzBVMzIb8zHKezI6trFc1zHHVhid3xaelzAVTz/yZsswdQYyBtMw0DswUiIyJisyJZMa6gMe598wXv8ypy8xuizyFzcyrsoy0UMy7OcxGg8wTEsyr6staWMwwaGywPsx7Ynw+2LcxKbvvLbzPQCzdHcc9QML9dcvuYrzfuSzdr8zNwcvz4XzuY7JOQsztN8zui8zuzczvDrzvAcz/I8z3c2vyLMxgyczxmsz/zczxjbyQ/qzwI90JBM0AZ90F9M0DuM0Az9xw390AcN0FEM0RRNxxV90Rid0IzQABwNAt7AAizwmZHQACgwCCSNCA1ADCANACBwAgrQAr4AAjDd0Av9CSctCCeNAiVtDgogCEWgADwQDC3g0Rl9rJPQ/wELsAA3MNOikNSI4NR8edQ9DQANgNSIMNW+4NQnQAMs7QoNMNUtENQ0TYql0AFTXdULAAArbQ4dAAAocAMgQNSrANU8wNRFrcZH7dM9vQAowNctrQBprdZFkAIpUNINkAIKcAIerQCAjQKHndgeDdW/fNQnkNIncAJp/diKDQBQfdgpkNKc3dc77dYssAAKwAItQNiGjdibndRvjdlqndgljQIs0ABpvQA/zQN/ndIo4NIpANNKvQAkHdIgYNoL4NENUAQundJ/vdmqfNAdUNkAcNmZndIsMNiFzdLGjdwNsNaCcN2EXdwKwNUAwAOMXQSC0NbBTdIuHdJU3d0sQP/bpo3aqk3VrL3YjR3f9v3Z343dJZ3agH3XcNwOba3WKQAAZs3XLpDSPJDWQA0CNHACANACJR3h013ZMl3hEi7ZIywJHZDaKJACTk3hAGDhVe3WN6DTKY7gjW3SN9AAIHADx23hJG7hSQ0CLkAD3Z0CINAAN0DVSiDiCB7Sqt0CP44CMG3kar3gjt3TsL0AG64ASP7jKcDVRWDXAW3QH17YIn7bDq7bFv7kG64EPODegvDgNLDgMV7S6L3mCL7kJP3iIJACIb0AZF7bci7jEC7hNS7hlw3jChDnKl7SaC7hSjDU5C3gc4jUPLDUbz7hMg7lPR3oVN3TEJ4CLrDXgX3/6ZnO2YE92R4OAIxt22nN6VPd1jQQ2AvA1QVOCF995in96qbu6aKe0vwt6i3w6uktCFBd4Czg0m2t66+uBINA7L0+3SlQBKMtOmQtCm096k7t1JQ+7MVO64Uw7VM97eatBCkd7D3dAmd94J2d7bFu6TSA6ZoO66nO61yN7QBwAzwA4wJe0DTYARw9CAXeAAvO0TDt7jne4+kOAP/+6hzep5bg7bQ+8Kdu7U7d6iZN7pUu8DQA8LRO6ZRe67r+6MfOAydQ0ggf8a2u3oHt6yfA7TXa7J+A8NHu4OX+6G9e8LUe8bVeBC7Q790e8cIe8Lru7xNP8IEd6FAt7S1/6Uog/9dFveiFUOAgcOiCYPMg79EssNdi3QFQH/CgHgkO3/BVv+st4AJnDtMOj9MQ/+pUH9sVn9I0ENQxLvMaP/Kijt4oEOxeH/HJbt/WHuyC0OAnj9BZ7+Ux/+p1f9jWTgjuXusLoPYL/ua6XvSczdXjDutPb/aHD+td//V/39OgnfiKjrZh3+pdrwAuwPIRzwI3kNg9jQKZ3gKkb/qD3+FYTwhOvfouveuc7QKhT/uuPvY9LfvpTuktbfvonfEFfuxGDtQFzti1/e2M/dJ3X/uMbfRZTtB9f/YRD+6MDdyfPgiFH+g4rgCYfvO6TvMu0NqBvfMtz/tunfqUvgC2//Mtj//pLiDWm8/FguwvIBD2827R+b//Rw8IAQCDhIWGh4iHAYKJjY6PkJGQi5KVlpcAJzcLmJ2en6ChopSipaanqKmqq6yRpKyvrbKKjLO2t7i5prG6vb6/wMGIvKnEwqO1x8rLzJbGzdDR0svPu8mdLTyXLCyw19Pg4brV4uXm553kyKENCpELnADw3uj19uv3+fr66qH9iSAWKEjhTp6CEyAANCCIEIACBQtQLOBxQkGDYt/2adz4b6PHj+Mynup4iAcnFu5MAijirgUKADROZDrRIKACFC1uYATJMx/JnkCD+hNpzZOShO0AKIG3oAMAEDRSuHA3T148p6h+Ct0akqv/169DZWklhDVphwZoL7qgASJp1apYRxIFS/fW2Lp4g96ttNfFRZYOaQxqAaBDQpTytFkdFLdo3sd250KerFdyWGwuUlR8KjUzABY3DrpDMbUF3J2UU6NWzbqyWMv29raePUg27dvMbE+CXU83bsq+fwvvFbxR8dy8h9M+rrw5vVbMlUV3vnU69euXn/O0jn178u7gta/iDox8eI3mz6sf9h1TeuLt1399L1++efq58Ncvp38/+PvxidOff9MMSCB19x2wyIIMNujggxBGKOGEEx6gIIUYZqjhhhx26OGHIIYo4iIWjmjiiSimqOKKLLaYoYKycODijDTWaOONOOaoW+OOPPbo448QcnDgkEQWaeSRSCap5JJMNunkk1BGKeWUVFZp5ZVYZqnlllx26eWXYIYp5phklmnmmWimqeaabLbp5ptwxinnnHTWaeedeOap55589unnn4CCEwgAOw==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_40_10880=[""].join("\n");
var outline_f10_40_10880=null;
var title_f10_40_10881="Varicella virus vaccine: Patient drug information";
var content_f10_40_10881=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Varicella virus vaccine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/28/4551?source=see_link\">",
"     see \"Varicella virus vaccine: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?12/5/12374?source=see_link\">",
"     see \"Varicella virus vaccine: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F233527\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Varivax&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F233528\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Varilrix&reg;;",
"     </li>",
"     <li>",
"      Varivax&reg; III",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt adi-os drugH1Div\" id=\"F10026005\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     CDC Information",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705779",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Vaccine Information Statements (VIS) are made by the staff of the Centers for Disease Control and Prevention (CDC). Each VIS gives information to properly inform the adult receiving the vaccine or, in the case of a minor, the child's parent or legal representative about the risks and benefits of each vaccine. Before a doctor vaccinates a child or an adult, the provider is required by the National Childhood Vaccine Injury Act to give a copy of the VIS. You can also get foreign language versions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705983",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <a href=\"file://www.immunize.org/vis/vis_chickenpox.asp\" target=\"_blank\">",
"        Vaccine Information Statements (VIS)",
"       </a>",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11925 Version 26.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-189.41.172.26-BC0FF6A85B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_40_10881=[""].join("\n");
var outline_f10_40_10881=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233527\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233528\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026005\">",
"      CDC Information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?4/28/4551?source=related_link\">",
"      Varicella virus vaccine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?12/5/12374?source=related_link\">",
"      Varicella virus vaccine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_40_10882="Intermediate anorectal malformation";
var content_f10_40_10882=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F62573&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F62573&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Rectal shelf in a three-month-old girl with an intermediate anorectal anomaly",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 312px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A)&nbsp;The anal opening is excentrically located in pigmented skin of perineum. The opening is not stenotic. B)&nbsp;To demonstrate the posterior shelf, a&nbsp;surgical clamp&nbsp;is inserted&nbsp;into the anal opening, pulling outward on the posterior lip of anorectal canal.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Hendren WH. Pediatric rectal and perineal problems. Pediatr Clin North Am 1998; 45:1353. Copyright &copy;1998 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_40_10882=[""].join("\n");
var outline_f10_40_10882=null;
var title_f10_40_10883="Dapsone (topical): Pediatric drug information";
var content_f10_40_10883=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"11\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Dapsone (topical): Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?43/34/44579?source=see_link\">",
"    see \"Dapsone (topical): Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?1/51/1844?source=see_link\">",
"    see \"Dapsone (topical): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F8016713\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Aczone&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F14965298\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Aczone&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F10483648\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?43/34/44579?source=see_link\">",
"      see \"Dapsone (topical): Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Acne vulgaris:",
"     </b>",
"     Children &ge;12 years, Adolescents, and Adults: Topical: Apply a pea-sized amount of gel to the acne-affected areas twice daily; re-evaluate patient if no improvement after 12 weeks of therapy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosage adjustment in renal impairment:",
"     </b>",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling; has not been studied.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosage adjustment in hepatic impairment:",
"     </b>",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling; has not been studied.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F8015348\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gel, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Aczone&reg;: 5% (30 g, 60 g)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F8015285\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F10483649\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Topical: Wash skin and pat dry then rub in thin layer of gel gently and completely. Wash hands after application.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F10483647\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Protect from freezing.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F10483644\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Topical treatment of acne vulgaris (FDA approved in ages 12-17 years and adults)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F8015284\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Dapsone may be confused with Diprosone&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F8015273\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiovascular: Facial edema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Central nervous system: Depression, psychosis, suicide attempt, tonic-clonic movement",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gastrointestinal: Abdominal pain, pancreatitis, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Local: Application site reactions including burning, dryness, erythema, oiliness/peeling, and pruritus were reported at an incidence similar to or less than placebo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Respiratory: Pharyngitis, sinusitis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F10483645\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to dapsone or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F15681711\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Changes suggestive of mild hemolysis have been observed in some patients with glucose-6-phosphate dehydrogenase (G-6-PD) deficiency and using dapsone gel; discontinue use with signs/symptoms of hemolytic anemia. Do not use concomitantly with oral dapsone, trimethoprim/sulfamethoxazole, or antimalarial medications; may increase the risk of hemolysis in patients with G-6-PD deficiency. Localized discoloration (yellow or orange) of the skin or facial hair may occur if benzoyl peroxide is used subsequent to dapsone gel; typically resolves in ~1-8 weeks. Vehicle used for product formulation may cause skin dryness, erythema, oiliness, and peeling; patients should be counseled about these effects.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F8015275\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2C19 (minor), CYP2C8 (minor), CYP2C9 (minor), CYP2E1 (minor), CYP3A4 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F8015276\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antimalarial Agents: May enhance the adverse/toxic effect of Dapsone (Topical). Specifically, the risk of hemolytic reactions may be increased. Management: Closely monitor for signs/symptoms of hemolytic reactions with concomitant use of topical dapsone and antimalarial agents. Patients with glucose-6-phosphate dehydrogenase deficiency may be at particularly high risk for adverse hematologic effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trimethoprim: May enhance the adverse/toxic effect of Dapsone (Topical). More specifically, trimethoprim may increase the risk for hemolysis",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F8085366\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F8085367\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Because of adverse events observed in some animal studies, dapsone is classified as pregnancy category C. Dapsone has not shown an increased risk of congenital anomalies when given orally during pregnancy; however, adverse effects in the newborn have been reported following",
"     <i>",
"      in utero",
"     </i>",
"     exposure. Refer to the Dapsone (Systemic) monograph for details. The amount of dapsone available systemically is less following topical application than with oral administration. During pregnancy, treatment for acne is often discontinued. If treatment is deemed necessary due to the risk of significant scarring or severe disease, dapsone is generally not the topical antibiotic of choice.",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F10483650\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?1/51/1844?source=see_link\">",
"      see \"Dapsone (topical): Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use exactly as directed; do not increase or discontinue without consulting prescriber. If no improvement after 12 weeks, consult prescriber. For external use only; avoid applying to inside nose, mouth, eyes, and mucous membranes. Gently wash skin and pat dry. Apply a small amount (pea size) and rub in gently and completely as frequently as directed (may appear gritty with visible particles). Wash hands after applying. Concurrent use with  topical benzoyl peroxide may result in temporary yellow or orange discoloration at the application site.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15962 Version 24.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-61.234.146.186-06EB330AA9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_40_10883=[""].join("\n");
var outline_f10_40_10883=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8016713\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14965298\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10483648\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8015348\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8015285\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10483649\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10483647\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10483644\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8015284\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8015273\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10483645\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15681711\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8015275\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8015276\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8085366\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8085367\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10483650\">",
"      Patient Information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/15962\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/15962|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?29/7/29814?source=related_link\">",
"      Dapsone (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?9/22/9573?source=related_link\">",
"      Dapsone (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/20/39237?source=related_link\">",
"      Dapsone (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?43/34/44579?source=related_link\">",
"      Dapsone (topical): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?1/51/1844?source=related_link\">",
"      Dapsone (topical): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_40_10884="Recombinant human factor VIIa: Patient drug information";
var content_f10_40_10884=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Recombinant human factor VIIa: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/42/30373?source=see_link\">",
"     see \"Recombinant human factor VIIa: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?43/18/44324?source=see_link\">",
"     see \"Recombinant human factor VIIa: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F169443\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      NovoSeven&reg; RT",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F169444\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Niastase&reg;;",
"     </li>",
"     <li>",
"      Niastase&reg; RT",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10110686\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2723539",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may cause blood clots. Tell your doctor right away if you have chest pain, shortness of breath, eyesight problems, bad belly pain, or pain or swelling of the legs or arms.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10011801\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691879",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat hemophilia.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691426",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop and treat bleeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10011800\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702100",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to Factor VIIa, mice, hamsters, cattle, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10011805\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697253",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have hardening of the arteries, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698421",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood pressure checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10011806\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698333",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Short-term pain after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698078",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Fever and chills.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698134",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       High blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697859",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Allergic side effects may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10011808\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698619",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in strength on 1 side is greater than the other, trouble speaking or thinking, change in balance, or blurred eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698626",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698967",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Joint pain or swelling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699057",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Big change in balance.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699095",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling, warmth, or pain in the leg or arm.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight, eye pain, or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10011803\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695991",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10011810\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11536 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.66.252.144-6F4C19BDB0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_40_10884=[""].join("\n");
var outline_f10_40_10884=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169443\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169444\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10110686\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011801\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011800\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011805\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011806\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011808\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011803\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011810\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?29/42/30373?source=related_link\">",
"      Recombinant human factor VIIa: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?43/18/44324?source=related_link\">",
"      Recombinant human factor VIIa: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_40_10885="Radial echoendoscope";
var content_f10_40_10885=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F62721&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F62721&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 476px\">",
"   <div class=\"ttl\">",
"    Radial echoendoscope tip entering the stomach",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 456px; height: 388px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The scanning plane (arrows) is perpendicular to the axis of the echoendoscope, providing cross-sectional views of the abdominal structures.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Lyndon V. Hernandez, MD and Manoop S. Bhutani, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_40_10885=[""].join("\n");
var outline_f10_40_10885=null;
var title_f10_40_10886="Budesonide in the treatment of Crohn's disease";
var content_f10_40_10886=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Budesonide in the treatment of Crohn's disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/40/10886/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/40/10886/contributors\">",
"     Mark A Peppercorn, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/40/10886/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/40/10886/contributors\">",
"     Paul Rutgeerts, MD, PhD, FRCP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/40/10886/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/40/10886/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/40/10886/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 5, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/7/32880?source=see_link\">",
"     Budesonide",
"    </a>",
"    is a glucocorticoid that has high affinity for the glucocorticoid receptor but low systemic activity due to extensive first-pass metabolism in the liver [",
"    <a class=\"abstract\" href=\"UTD.htm?10/40/10886/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Its use in a variety of steroid-responsive illnesses (such as asthma and allergic rhinitis) has demonstrated similar efficacy to conventional steroids, with less steroid toxicity or impact on the hypothalamic-pituitary-adrenal axis. Studies of budesonide in patients with Crohn's disease suggest that in addition to having fewer steroid-related side effects it is:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Effective for inducing remission in ileal or ileal cecal disease",
"     </li>",
"     <li>",
"      Probably ineffective for maintaining steroid-induced remission",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INDUCTION OF REMISSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies have examined the role of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/7/32880?source=see_link\">",
"     budesonide",
"    </a>",
"    in inducing remission in ileal and ileocecal Crohn's disease [",
"    <a class=\"abstract\" href=\"UTD.htm?10/40/10886/abstract/3-8\">",
"     3-8",
"    </a>",
"    ]. The following conclusions were reached in a systematic review that focused on eight controlled trials in which budesonide was compared with conventional glucocorticoids, 5-ASA, or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?10/40/10886/abstract/9\">",
"     9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/7/32880?source=see_link\">",
"       Budesonide",
"      </a>",
"      was superior to placebo for induction of remission (OR 2.85, 95% CI 1.67-4.87) based upon two trials.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/7/32880?source=see_link\">",
"       Budesonide",
"      </a>",
"      was more effective at inducing remission compared to 4 g per day of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/44/22215?source=see_link\">",
"       mesalamine",
"      </a>",
"      in one trial (62 versus 36 percent, RR 1.73, 95% CI 1.26-2.39) [",
"      <a class=\"abstract\" href=\"UTD.htm?10/40/10886/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/7/32880?source=see_link\">",
"       Budesonide",
"      </a>",
"      was inferior to conventional glucocorticoids (OR 0.69, 95% CI 0.51-0.95) based upon five trials.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Similar conclusions were reached in two earlier meta-analyses [",
"    <a class=\"abstract\" href=\"UTD.htm?10/40/10886/abstract/7,11\">",
"     7,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following observations illustrate the range of findings in some of the largest studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study, 176 patients with active ileal or ileocecal Crohn's disease were randomized to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/7/32880?source=see_link\">",
"       budesonide",
"      </a>",
"      (9 mg daily for eight weeks and then 6 mg daily for two weeks) or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"       prednisolone",
"      </a>",
"      (40 mg daily for two weeks after which it was tapered by 5 mg per day) [",
"      <a class=\"abstract\" href=\"UTD.htm?10/40/10886/abstract/4\">",
"       4",
"      </a>",
"      ]. After 10 weeks, the rate of clinical remission was similar between the two groups (53 and 66 percent respectively). Prednisolone reduced scores on the Crohn's disease activity index more than budesonide, but was associated with significantly more side effects.",
"     </li>",
"     <li>",
"      In another report, 258 patients with active Crohn's disease involving the ileum or proximal colon were randomly assigned to receive",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/7/32880?source=see_link\">",
"       budesonide",
"      </a>",
"      (3, 9, or 15 mg daily) or placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?10/40/10886/abstract/5\">",
"       5",
"      </a>",
"      ]. After eight weeks of treatment, remission occurred in 33, 51, and 43 percent in the 3, 9, or 15 mg budesonide groups, respectively, compared to 20 percent in patients receiving placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?10/40/10886/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a third randomized controlled trial of 201 patients with Crohn's disease of the terminal ileum or colon,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/7/32880?source=see_link\">",
"       budesonide",
"      </a>",
"      (9 mg once daily for eight weeks) was as effective as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      (40 mg once daily for two weeks with gradual tapering) for inducing remission (51 versus 53 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?10/40/10886/abstract/6\">",
"       6",
"      </a>",
"      ]. However, twice as many patients responded to treatment with budesonide without side effects compared to prednisone (30 versus 14 percent).",
"     </li>",
"     <li>",
"      In a more recent randomized trial of 309 patients with Crohn&rsquo;s disease of the terminal ileum (with or without involvement of the ascending colon) or descending colon,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/7/32880?source=see_link\">",
"       budesonide",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/44/22215?source=see_link\">",
"       mesalamine",
"      </a>",
"      were equally efficacious for inducing remission [",
"      <a class=\"abstract\" href=\"UTD.htm?10/40/10886/abstract/12\">",
"       12",
"      </a>",
"      ]. Patients were assigned to receive budesonide 9 mg once daily, budesonide 3 mg three times daily, or mesalamine 4.5 g daily. Remission rates did not vary among the three groups (67, 72, and 62 percent, respectively). In the subset of patients with Crohn&rsquo;s disease involving the distal colon, there was a trend toward higher remission rates in patients who received budesonide (77 versus 50 percent for mesalamine, p = 0.0512).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Not all studies used the same formulation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/7/32880?source=see_link\">",
"     budesonide",
"    </a>",
"    ; some [",
"    <a class=\"abstract\" href=\"UTD.htm?10/40/10886/abstract/3-5\">",
"     3-5",
"    </a>",
"    ] used a combined pH-dependent controlled-release preparation (available in the United States as Entocort EC), while others [",
"    <a class=\"abstract\" href=\"UTD.htm?10/40/10886/abstract/6,12,13\">",
"     6,12,13",
"    </a>",
"    ] used a pH-dependent-only release preparation [",
"    <a class=\"abstract\" href=\"UTD.htm?10/40/10886/abstract/14\">",
"     14",
"    </a>",
"    ]. These differences are potentially important when comparing the results of the different trials.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Budesonide plus antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antibiotics (such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    ) are used frequently in patients with active Crohn's disease. However, they do not appear to offer a benefit when used in addition to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/7/32880?source=see_link\">",
"     budesonide",
"    </a>",
"    in patients with active ileal disease, although they may have an additive benefit in patients who have ileocolonic disease.",
"   </p>",
"   <p>",
"    This was illustrated in a controlled trial in which 134 patients with active Crohn's disease were randomly assigned to a combination of oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    or placebo in addition to oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/7/32880?source=see_link\">",
"     budesonide",
"    </a>",
"    (9 mg daily) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/40/10886/abstract/15\">",
"     15",
"    </a>",
"    ]. At week 8, a similar proportion of patients in both groups were in remission (33 versus 38 percent in the antibiotic versus placebo groups, respectively). On subgroup analysis, a benefit to the combination therapy was observed among patients with active ileocolonic disease (remission rates at 8 weeks of 53 (9 of 17) versus 25 (4 of 16) percent). Discontinuation due to side effects was observed significantly more often in patients receiving antibiotics compared to those receiving placebo (20 versus 0 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     MAINTENANCE OF REMISSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Conventional glucocorticoids are ineffective in maintaining long-term remission in Crohn's disease, suggesting that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/7/32880?source=see_link\">",
"     budesonide",
"    </a>",
"    is not likely to be effective in this setting. Studies examining the effectiveness of budesonide in maintaining remission have produced disparate results [",
"    <a class=\"abstract\" href=\"UTD.htm?10/40/10886/abstract/13,16,17\">",
"     13,16,17",
"    </a>",
"    ]. While some suggested that it may delay time to relapse [",
"    <a class=\"abstract\" href=\"UTD.htm?10/40/10886/abstract/16\">",
"     16",
"    </a>",
"    ], others found that the likelihood of remission at one-year was similar to placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?10/40/10886/abstract/13,18,19\">",
"     13,18,19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    At least four meta-analyses examining the efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/7/32880?source=see_link\">",
"     budesonide",
"    </a>",
"    in maintaining remission have been published [",
"    <a class=\"abstract\" href=\"UTD.htm?10/40/10886/abstract/7,11,20,21\">",
"     7,11,20,21",
"    </a>",
"    ]. The most recent, which focused on 11 studies, concluded that budesonide was not more effective than placebo for maintaining remission [",
"    <a class=\"abstract\" href=\"UTD.htm?10/40/10886/abstract/21\">",
"     21",
"    </a>",
"    ]. Some modest benefits were noted in lowering disease activity scores and prolonging time to relapse of disease but these benefits were considered to be offset by higher treatment-related adverse effects (mainly adrenal suppression). A later randomized controlled trial involving 38 patients with steroid dependent Crohn's ileocolitis or proximal colitis found that budesonide was significantly less effective than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    in maintaining remission at one year [",
"    <a class=\"abstract\" href=\"UTD.htm?10/40/10886/abstract/22\">",
"     22",
"    </a>",
"    ]. Budesonide (6 mg daily) has received approval from the United States Food and Drug Administration for maintenance of clinical remission in mild to moderate Crohn's disease involving the ileum",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ascending colon for up to three months.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     EFFECT ON BONE MINERAL DENSITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are few studies addressing the effect of oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/7/32880?source=see_link\">",
"     budesonide",
"    </a>",
"    on bone metabolism. However, the available data suggest that it may not avoid steroid-induced bone loss.",
"   </p>",
"   <p>",
"    An initial study compared biochemical markers of bone turnover in 29 patients with Crohn's disease treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    (32 mg) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/7/32880?source=see_link\">",
"     budesonide",
"    </a>",
"    (9 mg) for ten weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?10/40/10886/abstract/23\">",
"     23",
"    </a>",
"    ]. Methylprednisolone treatment was associated with significant suppression of serum osteocalcin (a measure of bone synthesis) while no change was observed in the budesonide group suggesting that budesonide may not be associated with bone loss.",
"   </p>",
"   <p>",
"    Different conclusions were reached in a non-randomized, prospective study of 138 patients with quiescent Crohn's disease, which compared the effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/7/32880?source=see_link\">",
"     budesonide",
"    </a>",
"    (mean daily dose of 8.5 mg),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    (mean daily dose of 10.5 mg), and treatment with non-steroid containing agents during two-years of follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?10/40/10886/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Between baseline and one-year, mean bone mineral density in the femoral neck decreased significantly more in the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/7/32880?source=see_link\">",
"     budesonide",
"    </a>",
"    group compared with the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    group. The differences continued to be apparent at two years. The proportion of patients with bone loss of greater than 2 percent per year in the lumbar spine and femoral neck was significantly higher in the budesonide group compared with the prednisone or non-steroid groups. The authors concluded that budesonide does not confer an advantage over low-dose prednisone for preservation of bone mineral density.",
"   </p>",
"   <p>",
"    A subsequent controlled trial included 272 patients with Crohn's disease involving the ileum",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ascending colon who were randomly assigned to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/7/32880?source=see_link\">",
"     budesonide",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    for two years at doses adapted to disease activity [",
"    <a class=\"abstract\" href=\"UTD.htm?10/40/10886/abstract/25\">",
"     25",
"    </a>",
"    ]. No significant differences were observed in bone mineral density among glucocorticoid-free, budesonide treated, or prednisolone treated patients. However, the reduction in bone mineral density was significantly less in patients who had never before received glucocorticoids and were subsequently treated with budesonide compared with those receiving prednisolone. Efficacy was similar in both groups. The authors concluded that treatment with budesonide was associated with better preservation of bone mineral density only in glucocorticoid-naive patients with active ileocecal Crohn's disease. There were only few fractures during follow-up making, occurring in both the budesonide and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    groups; thus, a benefit of budesonide on fracture reduction could not be demonstrated.",
"   </p>",
"   <p>",
"    Data regarding the safety of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/7/32880?source=see_link\">",
"     budesonide",
"    </a>",
"    with respect to bone mineral metabolism are inconclusive. Until further data are available, patients who require long-term use should have bone mineral density monitored yearly. Patients should also receive vitamin D (400 to 800",
"    <span class=\"nowrap\">",
"     units/day)",
"    </span>",
"    and calcium supplementation (1000 to 1500",
"    <span class=\"nowrap\">",
"     mg/day).",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/54/42855?source=see_link\">",
"     \"Pathogenesis, clinical features, and evaluation of glucocorticoid-induced osteoporosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/54/30569?source=see_link&amp;anchor=H16#H16\">",
"     \"Metabolic bone disease in inflammatory bowel disease\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     ADRENAL SUPPRESSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/7/32880?source=see_link\">",
"     Budesonide",
"    </a>",
"    can reduce the response of the hypothalamus pituitary adrenal axis to stress but to a lesser extent than conventional glucocorticoids&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?10/40/10886/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. As a result, substitution of a glucocorticoid with high systemic effects to budesonide should be done cautiously. In addition, supplementation with a systemic glucocorticoid may be required in patients taking budesonide who undergo surgery or other stress situations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?9/56/10115?source=see_link\">",
"       \"Patient information: Crohn's disease in adults (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?23/40/24196?source=see_link\">",
"       \"Patient information: Crohn's disease (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following summarizes the data presented above. An approach to patients with Crohn's disease is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/54/19305?source=see_link\">",
"     \"Overview of the medical management of mild to moderate Crohn's disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Trials comparing",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/7/32880?source=see_link\">",
"       budesonide",
"      </a>",
"      with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/44/22215?source=see_link\">",
"       mesalamine",
"      </a>",
"      for the induction of remission have reached variable conclusions. One trial found that budesonide was superior, while another found no difference. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Induction of remission'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/7/32880?source=see_link\">",
"       Budesonide",
"      </a>",
"      is less effective than conventional glucocorticoids in inducing clinical remission but is associated with significantly fewer glucocorticoid-associated adverse events. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Induction of remission'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/7/32880?source=see_link\">",
"       Budesonide",
"      </a>",
"      (in a dual pH-dependent controlled-release formulation) has received approval from the United States Food and Drug Administration for maintenance of clinical remission in mild to moderate Crohn's disease involving the ileum",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      ascending colon for up to three months. A benefit on maintaining remission for longer periods has not been established. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Maintenance of remission'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Data regarding the safety of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/7/32880?source=see_link\">",
"       budesonide",
"      </a>",
"      with respect to bone mineral metabolism are inconclusive. Until further data are available, patients who require long-term use should have bone mineral density monitored yearly. Patients should also receive vitamin D (400 to 800",
"      <span class=\"nowrap\">",
"       units/day)",
"      </span>",
"      and calcium supplementation (1000 to 1500",
"      <span class=\"nowrap\">",
"       mg/day).",
"      </span>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/54/42855?source=see_link\">",
"       \"Pathogenesis, clinical features, and evaluation of glucocorticoid-induced osteoporosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/54/30569?source=see_link&amp;anchor=H16#H16\">",
"       \"Metabolic bone disease in inflammatory bowel disease\", section on 'Treatment'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/7/32880?source=see_link\">",
"       Budesonide",
"      </a>",
"      can reduce the response of the hypothalamus pituitary adrenal axis to stress but to a lesser extent than conventional glucocorticoids. As a result, substitution of a glucocorticoid with high systemic effects to budesonide should be done cautiously. In addition, supplementation with a systemic glucocorticoid may be required in patients taking budesonide who undergo surgery or other stress situations. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Adrenal suppression'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/40/10886/abstract/1\">",
"      Brattsand R. Overview of newer glucocorticosteroid preparations for inflammatory bowel disease. Can J Gastroenterol 1990; 4:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/40/10886/abstract/2\">",
"      Dahlstrom K, Edsbacker S, Kallen A. Rectal pharmacokinetics of budesonide. Eur J Clin Pharmacol 1996; 49:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/40/10886/abstract/3\">",
"      Campieri M, Ferguson A, Doe W, et al. Oral budesonide is as effective as oral prednisolone in active Crohn's disease. The Global Budesonide Study Group. Gut 1997; 41:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/40/10886/abstract/4\">",
"      Rutgeerts P, L&ouml;fberg R, Malchow H, et al. A comparison of budesonide with prednisolone for active Crohn's disease. N Engl J Med 1994; 331:842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/40/10886/abstract/5\">",
"      Greenberg GR, Feagan BG, Martin F, et al. Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group. N Engl J Med 1994; 331:836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/40/10886/abstract/6\">",
"      Bar-Meir S, Chowers Y, Lavy A, et al. Budesonide versus prednisone in the treatment of active Crohn's disease. The Israeli Budesonide Study Group. Gastroenterology 1998; 115:835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/40/10886/abstract/7\">",
"      Papi C, Luchetti R, Gili L, et al. Budesonide in the treatment of Crohn's disease: a meta-analysis. Aliment Pharmacol Ther 2000; 14:1419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/40/10886/abstract/8\">",
"      Tremaine WJ, Hanauer SB, Katz S, et al. Budesonide CIR capsules (once or twice daily divided-dose) in active Crohn's disease: a randomized placebo-controlled study in the United States. Am J Gastroenterol 2002; 97:1748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/40/10886/abstract/9\">",
"      Otley A, Steinhart AH. Budesonide for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2005; :CD000296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/40/10886/abstract/10\">",
"      Thomsen OO, Cortot A, Jewell D, et al. A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide-Mesalamine Study Group. N Engl J Med 1998; 339:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/40/10886/abstract/11\">",
"      Kane SV, Schoenfeld P, Sandborn WJ, et al. The effectiveness of budesonide therapy for Crohn's disease. Aliment Pharmacol Ther 2002; 16:1509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/40/10886/abstract/12\">",
"      Tromm A, Bungani I, Tomsov&aacute; E, et al. Budesonide 9 mg is at least as effective as mesalamine 4.5 g in patients with mildly to moderately active Crohn's disease. Gastroenterology 2011; 140:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/40/10886/abstract/13\">",
"      Gross V, Andus T, Ecker KW, et al. Low dose oral pH modified release budesonide for maintenance of steroid induced remission in Crohn's disease. The Budesonide Study Group. Gut 1998; 42:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/40/10886/abstract/14\">",
"      Edsb&auml;cker S, Andersson T. Pharmacokinetics of budesonide (Entocort EC) capsules for Crohn's disease. Clin Pharmacokinet 2004; 43:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/40/10886/abstract/15\">",
"      Steinhart AH, Feagan BG, Wong CJ, et al. Combined budesonide and antibiotic therapy for active Crohn's disease: a randomized controlled trial. Gastroenterology 2002; 123:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/40/10886/abstract/16\">",
"      L&ouml;fberg R, Rutgeerts P, Malchow H, et al. Budesonide prolongs time to relapse in ileal and ileocaecal Crohn's disease. A placebo controlled one year study. Gut 1996; 39:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/40/10886/abstract/17\">",
"      Hellers G, Cortot A, Jewell D, et al. Oral budesonide for prevention of postsurgical recurrence in Crohn's disease. The IOIBD Budesonide Study Group. Gastroenterology 1999; 116:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/40/10886/abstract/18\">",
"      Hanauer S, Sandborn WJ, Persson A, Persson T. Budesonide as maintenance treatment in Crohn's disease: a placebo-controlled trial. Aliment Pharmacol Ther 2005; 21:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/40/10886/abstract/19\">",
"      Ferguson A, Campieri M, Doe W, et al. Oral budesonide as maintenance therapy in Crohn's disease--results of a 12-month study. Global Budesonide Study Group. Aliment Pharmacol Ther 1998; 12:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/40/10886/abstract/20\">",
"      Sandborn WJ, L&ouml;fberg R, Feagan BG, et al. Budesonide for maintenance of remission in patients with Crohn's disease in medically induced remission: a predetermined pooled analysis of four randomized, double-blind, placebo-controlled trials. Am J Gastroenterol 2005; 100:1780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/40/10886/abstract/21\">",
"      Benchimol EI, Seow CH, Otley AR, Steinhart AH. Budesonide for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 2009; :CD002913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/40/10886/abstract/22\">",
"      Mantzaris GJ, Christidou A, Sfakianakis M, et al. Azathioprine is superior to budesonide in achieving and maintaining mucosal healing and histologic remission in steroid-dependent Crohn's disease. Inflamm Bowel Dis 2009; 15:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/40/10886/abstract/23\">",
"      D'Haens G, Verstraete A, Cheyns K, et al. Bone turnover during short-term therapy with methylprednisolone or budesonide in Crohn's disease. Aliment Pharmacol Ther 1998; 12:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/40/10886/abstract/24\">",
"      Cino M, Greenberg GR. Bone mineral density in Crohn's disease: a longitudinal study of budesonide, prednisone, and nonsteroid therapy. Am J Gastroenterol 2002; 97:915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/40/10886/abstract/25\">",
"      Schoon EJ, Bollani S, Mills PR, et al. Bone mineral density in relation to efficacy and side effects of budesonide and prednisolone in Crohn's disease. Clin Gastroenterol Hepatol 2005; 3:113.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4061 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-183.1.191.153-3399DFF423-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_40_10886=[""].join("\n");
var outline_f10_40_10886=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H8\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INDUCTION OF REMISSION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Budesonide plus antibiotics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      MAINTENANCE OF REMISSION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      EFFECT ON BONE MINERAL DENSITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      ADRENAL SUPPRESSION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/54/30569?source=related_link\">",
"      Metabolic bone disease in inflammatory bowel disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/54/19305?source=related_link\">",
"      Overview of the medical management of mild to moderate Crohn's disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/54/42855?source=related_link\">",
"      Pathogenesis, clinical features, and evaluation of glucocorticoid-induced osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?23/40/24196?source=related_link\">",
"      Patient information: Crohn's disease (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?9/56/10115?source=related_link\">",
"      Patient information: Crohn's disease in adults (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_40_10887="PMLE pathology";
var content_f10_40_10887=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F65837&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F65837&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Polymorphous light eruption, histopathology",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Marked papillary edema and a superficial and deep lymphocytic infiltrate are visible in this specimen from a patient with polymorphous light eruption.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Copyright &copy; Greg Hosler, MD, PhD, Dermatlas;",
"     <a href=\"file://www.dermatlas.org\" target=\"_blank\">",
"      file://www.dermatlas.org",
"     </a>",
"     .",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_40_10887=[""].join("\n");
var outline_f10_40_10887=null;
var title_f10_40_10888="Ibuprofen, pseudoephedrine, and chlorpheniramine: Drug information";
var content_f10_40_10888=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ibuprofen, pseudoephedrine, and chlorpheniramine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?29/43/30389?source=see_link\">",
"    see \"Ibuprofen, pseudoephedrine, and chlorpheniramine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F744621\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Advil&reg; Allergy Sinus;",
"     </li>",
"     <li>",
"      Advil&reg; Multi-Symptom Cold",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F854890\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Advil&reg; Cold and Sinus Nighttime;",
"     </li>",
"     <li>",
"      Advil&reg; Cold and Sinus Plus;",
"     </li>",
"     <li>",
"      Children's Advil&reg; Cold and Flu Multi-Symptom",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F744625\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Alkylamine Derivative;",
"     </li>",
"     <li>",
"      Alpha-/Beta- Agonist;",
"     </li>",
"     <li>",
"      Decongestant;",
"     </li>",
"     <li>",
"      Histamine H;",
"      <sub>",
"       1",
"      </sub>",
"      Antagonist",
"     </li>",
"     <li>",
"      Histamine H;",
"      <sub>",
"       1",
"      </sub>",
"      Antagonist, First Generation",
"     </li>",
"     <li>",
"      Nonsteroidal Anti-inflammatory Drug (NSAID), Oral",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F744649\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-right:0em;margin-top:0em;text-align:justify;display:inline\">",
"     <b>",
"      Common cold, hay fever, respiratory allergies:",
"     </b>",
"     Oral: One caplet every 4-6 hours while symptoms persist (maximum: 6 caplets/24 hours); treatment for &gt;10 days is not recommended unless directed by healthcare provider",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F744648\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-right:0em;margin-top:0em;text-align:justify;display:inline\">",
"     <b>",
"      Common cold, hay fever, respiratory allergies",
"     </b>",
"     : Oral: Children &ge;12 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F744651\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-right:0em;margin-top:0em;text-align:justify;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F744655\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Caplet:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Advil&reg; Allergy Sinus, Advil&reg; Multi-Symptom Cold:  Ibuprofen 200 mg, pseudoephedrine hydrochloride 30 mg, and chlorpheniramine maleate 2 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F744623\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F744652\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-right:0em;margin-top:0em;text-align:justify;display:inline\">",
"     May be administered with food or milk if stomach upset occurs.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F744627\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-right:0em;margin-top:0em;text-align:justify;display:inline\">",
"     Temporary relief of symptoms associated with the common cold, hay fever, or other respiratory allergies",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F744635\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-right:0em;margin-top:0em;text-align:justify;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F744630\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-right:0em;margin-top:0em;text-align:justify;display:inline\">",
"     Hypersensitivity to ibuprofen, pseudoephedrine, chlorpheniramine, or any component of the formulation; use with or within 2 weeks of an MAO inhibitor (MAO-I); immediately prior to or after coronary bypass graft (CABG) surgery",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F744631\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anaphylactoid reactions: Even in patients without prior exposure anaphylactoid reactions may occur; patients with \"aspirin triad\" (bronchial asthma, aspirin intolerance, rhinitis) may be at increased risk. Do not use in patients who experience bronchospasm, asthma, rhinitis, or urticaria with NSAID or aspirin therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular events: NSAIDs are associated with an increased risk of adverse cardiovascular events, including MI, stroke, and new onset or worsening of pre-existing hypertension. Risk may be increased with duration of use or pre-existing cardiovascular risk factors or disease. Carefully evaluate individual cardiovascular risk profiles prior to prescribing. Use caution with fluid retention. Avoid use in heart failure. Concurrent administration of ibuprofen, and potentially other nonselective NSAIDs, may interfere with aspirin&rsquo;s cardioprotective effect. Use the lowest effective dose for the shortest duration of time, consistent with individual patient goals, to reduce risk of cardiovascular events; alternate therapies should be considered for patients at high risk.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS effects: May cause drowsiness, dizziness, blurred vision, and other neurologic effects which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving). Discontinue use with blurred or diminished vision and perform ophthalmologic exam. Periodically evaluate vision in all patients receiving long-term therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gastrointestinal events: NSAIDs may increase risk of gastrointestinal irritation, inflammation, ulceration, bleeding, and perforation. These events may occur at any time during therapy and without warning. Use caution with a history of GI disease (bleeding or ulcers), concurrent therapy with aspirin, anticoagulants and/or corticosteroids, smoking, use of alcohol, the elderly or debilitated patients. Use the lowest effective dose for the shortest duration of time, consistent with individual patient goals, to reduce risk of GI adverse events; alternate therapies should be considered for patients at high risk. When used concomitantly with &le;325 mg of aspirin, a substantial increase in the risk of gastrointestinal complications (eg, ulcer) occurs; concomitant gastroprotective therapy (eg, proton pump inhibitors) is recommended (Bhatt, 2008).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hematologic effects: Platelet adhesion and aggregation may be decreased; may prolong bleeding time; patients with coagulation disorders or who are receiving anticoagulants should be monitored closely. Anemia may occur; patients on long-term NSAID therapy should be monitored for anemia. Rarely, NSAID use has been associated with potentially severe blood dyscrasias (eg, agranulocytosis, thrombocytopenia, aplastic anemia).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperkalemia: NSAID use may increase the risk of hyperkalemia, particularly in the elderly, diabetics, renal disease, and with concomitant use of other agents capable of inducing hyperkalemia (eg, ACE-inhibitors). Monitor potassium closely.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Skin reactions: NSAIDs may cause serious skin adverse events including exfoliative dermatitis, Stevens-Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN); discontinue use at first sign of skin rash or hypersensitivity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Aseptic meningitis: May increase the risk of aseptic meningitis, especially in patients with systemic lupus erythematosus (SLE) and mixed connective tissue disorders.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Asthma: Do not administer to patients with aspirin-sensitive asthma; severe bronchospasm may occur. Use caution in patients with other forms of asthma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Coronary artery bypass graft surgery: Use is contraindicated when used immediately prior to or after coronary artery bypass graft (CABG) surgery. Risk of MI and stroke may be increased with use following CABG surgery.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use with caution in patients with diabetes mellitus.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with decreased hepatic function. Closely monitor patients with any abnormal LFT. Severe hepatic reactions (eg, fulminant hepatitis, liver failure) have occurred with NSAID use, rarely; discontinue if signs or symptoms of liver disease develop, or if systemic manifestations occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypertension: Use with caution; may cause new-onset hypertension or worsening of existing hypertension.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Increased intraocular pressure/glaucoma: Use with caution in patients with increased intraocular pressure or angle-closure glaucoma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Prostatic hyperplasia/urinary obstruction: Use with caution in patients with prostatic hyperplasia and/or urinary obstruction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: NSAID use may compromise existing renal function; dose-dependent decreases in prostaglandin synthesis may result from NSAID use, reducing renal blood flow which may cause renal decompensation. Patients with impaired renal function, dehydration, heart failure, liver dysfunction, those taking diuretics, and ACE inhibitors, and the elderly are at greater risk of renal toxicity. Rehydrate patient before starting therapy; monitor renal function closely. Not recommended for use in patients with advanced renal disease. Long-term NSAID use may result in renal papillary necrosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thyroid disease: Use with caution in patients with thyroid disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sedatives: Effects may be potentiated when used with other sedative drugs or ethanol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: The elderly are at increased risk for adverse effects (especially peptic ulceration, CNS effects, renal toxicity) from NSAIDs even at low doses.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Not for self-medication (OTC use) in children &lt;12 years of age.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Self-medication (OTC use): Prior to self-medication, patients should contact healthcare provider if they have had recurring stomach pain or upset, ulcers, bleeding problems, asthma, emphysema, chronic bronchitis, high blood pressure, heart or kidney disease, thyroid disease, diabetes, glaucoma, enlarged prostate, other serious medical problems, are currently taking a diuretic, aspirin, anticoagulant, sedative or tranquilizer, or are &ge;60 years of age. Recommended dosages should not be exceeded, due to an increased risk of GI bleeding. Stop use and consult a healthcare provider if symptoms get worse, newly appear, or continue; if an allergic reaction occurs; if nervousness, dizziness, or sleeplessness occurs; or if fever lasts for &gt;3 days, congestion lasts for &gt;7 days, or pain &gt;10 days. Consuming &ge;3 alcoholic beverages/day or taking longer than recommended may increase the risk of GI bleeding.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299504\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F744640\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abiraterone Acetate: May increase the serum concentration of CYP2D6 Substrates. Management: Avoid concurrent use of abiraterone with CYP2D6 substrates that have a narrow therapeutic index whenever possible.  When concurrent use is not avoidable, monitor patients closely for signs/symptoms of toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): Anticholinergics may diminish the therapeutic effect of Acetylcholinesterase Inhibitors (Central). Acetylcholinesterase Inhibitors (Central) may diminish the therapeutic effect of Anticholinergics. If the anticholinergic action is a side effect of the agent, the result may be beneficial.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aclidinium: May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the anticoagulant effect of other Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Agents with Antiplatelet Properties. An increased risk of bleeding may occur. Nonsteroidal Anti-Inflammatory Agents may diminish the cardioprotective effect of Agents with Antiplatelet Properties. This interaction is likely specific to aspirin, and not to other antiplatelet agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aliskiren: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Aliskiren. Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of Aliskiren.  Management: Monitor renal function periodically in patients receiving aliskiren and any nonsteroidal anti-inflammatory agent.  Patients at elevated risk of renal dysfunction include those who are elderly, are volume depleted, or have pre-existing renal dysfunction.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Blockers: May diminish the hypertensive effect of Alpha-/Beta-Agonists. Similarly, Alpha-/Beta-Agonists may antagonize hypotensive effects of Alpha1-Blockers. Alpha1-Blockers may diminish the vasoconstricting effect of Alpha-/Beta-Agonists. Similarly, Alpha-/Beta-Agonists may antagonize Alpha1-Blocker vasodilation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoglycosides: Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: May diminish the sedative effect of Antihistamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Angiotensin II Receptor Blockers: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Angiotensin II Receptor Blockers. The combination of these two agents may also significantly decrease glomerular filtration and renal function.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the excretion of Alpha-/Beta-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Aluminum Hydroxide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergics: May enhance the adverse/toxic effect of other Anticholinergics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticoagulants: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticoagulants: Nonsteroidal Anti-Inflammatory Agents may enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidepressants (Tricyclic, Tertiary Amine): May enhance the antiplatelet effect of NSAID (Nonselective).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzylpenicilloyl Polylysine: Antihistamines may diminish the diagnostic effect of Benzylpenicilloyl Polylysine.  Management: Suspend systemic H1 antagonists for benzylpenicilloyl-polylysine skin testing and delay testing until systemic antihistaminic effects have dissipated. A histamine skin test may be used to assess persistent antihistaminic effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzylpenicilloyl Polylysine: Alpha-/Beta-Agonists may diminish the diagnostic effect of Benzylpenicilloyl Polylysine.  Management: Consider use of a histamine skin test as a positive control to assess a patient's ability to mount a wheal and flare response.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levobunolol; Metipranolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Betahistine: Antihistamines may diminish the therapeutic effect of Betahistine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the absorption of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bisphosphonate Derivatives: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Bisphosphonate Derivatives. Both an increased risk of gastrointestinal ulceration and an increased risk of nephrotoxicity are of concern.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bromocriptine: Alpha-/Beta-Agonists may enhance the adverse/toxic effect of Bromocriptine. Including increased blood pressure, ventricular arrhythmias, and seizure.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cannabinoids: May enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carbonic Anhydrase Inhibitors: May decrease the excretion of Alpha-/Beta-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Brinzolamide; Dorzolamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Collagenase (Systemic): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May enhance the adverse/toxic effect of NSAID (Nonselective).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of CycloSPORINE (Systemic). Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of CycloSPORINE (Systemic). CycloSPORINE (Systemic) may increase the serum concentration of Nonsteroidal Anti-Inflammatory Agents. Specifically, elevated diclofenac concentrations have been reported.  Management: Consider alternatives to nonsteroidal anti-inflammatory agents (NSAIDs).  Monitor for evidence of nephrotoxicity, as well as increased serum cyclosporine concentrations and systemic effects (e.g., hypertension) during concomitant therapy with NSAIDs.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Moderate): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Strong): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Dabigatran Etexilate. Agents with Antiplatelet Properties may increase the serum concentration of Dabigatran Etexilate. This mechanism applies specifically to clopidogrel.  Management: Increase monitoring for signs/symptoms of bleeding. The Canadian product monograph for dabigatran specifically recommends avoiding concomitant use with GIIb/IIIa inhibitors or ticlopidine, or with aspirin used for stroke prevention in atrial fibrillation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Darunavir: May increase the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May enhance the anticoagulant effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Desmopressin: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Desmopressin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Digoxin: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Digoxin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Drotrecogin Alfa (Activated): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Drotrecogin Alfa (Activated). Bleeding may occur.  Management: When possible, avoid use of drotrecogin within 7 days of use of any IIb/IIIa antagonists, higher dose aspirin (more than 650 mg/day), or use of other antiplatelet agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Eplerenone. Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Eplerenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergot Derivatives: May enhance the hypertensive effect of Alpha-/Beta-Agonists. Ergot Derivatives may enhance the vasoconstricting effect of Alpha-/Beta-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Ergoloid Mesylates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FentaNYL: Alpha-/Beta-Agonists (Indirect-Acting) may decrease the serum concentration of FentaNYL. Specifically, fentanyl nasal spray serum concentrations may decrease and onset of effect may be delayed.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Floctafenine: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Glucosamine: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Haloperidol: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Haloperidol. Specifically including drowsiness and confusion.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Bleeding may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Bleeding may occur. Management: Concomitant treatment with these agents should generally be avoided. If used concomitantly, increased diligence in monitoring for adverse effects (eg, bleeding, bruising, altered mental status due to CNS bleeds) must be employed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Antihistamines may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving antihistamines (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrALAZINE: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of HydrALAZINE.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ibritumomab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Imatinib: Ibuprofen may decrease the serum concentration of Imatinib. Specifically, ibuprofen may decrease intracellular concentrations of imatinib, leading to decreased clinical response.  Management: Consider using an alternative to ibuprofen in patients who are being treated with imatinib.  Available evidence suggests other NSAIDs do not interact in a similar manner.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Sympathomimetics may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Nasal): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Systemic): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Lithium.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: Nonsteroidal Anti-Inflammatory Agents may diminish the diuretic effect of Loop Diuretics.  Management: Monitor for decreased therapeutic effects of loop diuretics with concurrent use of an NSAID. Consider avoiding concomitant use of these agents in CHF or cirrhosis with ascites. Concomitant use of bumetanide with indomethacin is  not recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the hypertensive effect of Alpha-/Beta-Agonists (Indirect-Acting).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrexate: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Methotrexate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. An increased risk of bleeding may occur. Nonsteroidal Anti-Inflammatory Agents may diminish the cardioprotective effect of Agents with Antiplatelet Properties. This interaction is likely specific to aspirin, and not to other antiplatelet agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May enhance the adverse/toxic effect of other Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (COX-2 Inhibitor): Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of NSAID (COX-2 Inhibitor).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omacetaxine: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Omacetaxine. Specifically, the risk for bleeding-related events may be increased.  Management: Avoid concurrent use of nonsteroidal antiinflammatory drugs (NSAIDs) with omacetaxine in patients with a platelet count of less than 50,000/uL.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omega-3 Fatty Acids: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PEMEtrexed: NSAID (Nonselective) may increase the serum concentration of PEMEtrexed.  Management: Patients with mild-to-moderate renal insufficiency (estimated creatinine clearance 45-79 mL/min) should avoid NSAIDs for 2-5 days prior to, the day of, and 2 days after pemetrexed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentosan Polysulfate Sodium: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Specifically, the risk of bleeding may be increased by concurrent use of these agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium-Sparing Diuretics: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Potassium-Sparing Diuretics. Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Potassium-Sparing Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PRALAtrexate: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of PRALAtrexate. More specifically, NSAIDS may decrease the renal excretion of pralatrexate.  Management: Closely monitor for increased pralatrexate serum levels and/or toxicity if used concomitantly with an NSAID. Monitor for decreased pralatrexate serum levels with NSAID discontinuation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramlintide: May enhance the anticholinergic effect of Anticholinergics. These effects are specific to the GI tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May increase the serum concentration of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: Nonsteroidal Anti-Inflammatory Agents may enhance the neuroexcitatory and/or seizure-potentiating effect of Quinolone Antibiotics. Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Quinolone Antibiotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Rivaroxaban.  Management: Avoid concurrent use of clopidogrel with rivaroxaban unless the anticipated benefits outweigh the risks of bleeding.  Avoid concurrent use of rivaroxaban with other antiplatelet agents whenever possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: NSAID (Nonselective) may enhance the adverse/toxic effect of Salicylates. An increased risk of bleeding may be associated with use of this combination. NSAID (Nonselective) may diminish the cardioprotective effect of Salicylates. Salicylates may decrease the serum concentration of NSAID (Nonselective).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Choline Magnesium Trisalicylate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Salicylates. Increased risk of bleeding may result.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May enhance the antiplatelet effect of NSAID (Nonselective). NSAID (Nonselective) may diminish the therapeutic effect of Selective Serotonin Reuptake Inhibitors. Management: Consider using alternative analgesics, when appropriate, and/or addition of an gastroprotective agent.  Monitor patients closely for signs/symptoms of bleeding, and for evidence of diminished SSRI effectiveness with concurrent use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin/Norepinephrine Reuptake Inhibitors: May enhance the tachycardic effect of Alpha-/Beta-Agonists. Serotonin/Norepinephrine Reuptake Inhibitors may enhance the vasopressor effect of Alpha-/Beta-Agonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin/Norepinephrine Reuptake Inhibitors: May enhance the antiplatelet effect of NSAID (Nonselective).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: May enhance the nephrotoxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the risk of acute phosphate nephropathy may be enhanced. Management: Consider avoiding this combination by temporarily suspending treatment with NSAIDs, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, maintain adequate hydration and monitor renal function closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Spironolactone: May diminish the vasoconstricting effect of Alpha-/Beta-Agonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thrombolytic Agents: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thrombolytic Agents: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Thrombolytic Agents. An increased risk of bleeding may occur.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiotropium: Anticholinergics may enhance the anticholinergic effect of Tiotropium.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tositumomab and Iodine I 131 Tositumomab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Tositumomab and Iodine I 131 Tositumomab. Specifically, the risk of bleeding-related adverse events may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Treprostinil: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Bleeding may occur.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vancomycin: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Vancomycin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin E: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): NSAID (Nonselective) may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Voriconazole: May increase the serum concentration of Ibuprofen. Specifically, concentrations of the S-(+)-ibuprofen enantiomer may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F744642\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-right:0em;margin-top:0em;text-align:justify;display:inline\">",
"     Ethanol: Avoid ethanol (may increase CNS depression and/or enhance gastric mucosal irritation).",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F744628\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-right:0em;margin-top:0em;text-align:justify;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F744629\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-right:0em;margin-top:0em;text-align:justify;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F744650\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-right:0em;margin-top:0em;text-align:justify;display:inline\">",
"     May be taken with food or milk if stomach upset occurs.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16324123\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Advil Allergy Sinus Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2-30-200 mg (20): $9.95",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F854891\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Advil Cold and Sinus Plus (CA)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F744645\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-right:0em;margin-top:0em;text-align:justify;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Bhatt DL, Scheiman J, Abraham NS, et al, &ldquo;ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risk of Antiplatelet Therapy and NSAID Use. A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2008, 52(18):1502-17.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/40/10888/abstract-text/19017521/pubmed\" id=\"19017521\" target=\"_blank\">",
"        19017521",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9008 Version 40.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-199.231.185.123-894C5EFDCE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_40_10888=[""].join("\n");
var outline_f10_40_10888=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F744621\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F854890\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F744625\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F744649\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F744648\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F744651\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F744655\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F744623\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F744652\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F744627\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F744635\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F744630\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F744631\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299504\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F744640\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F744642\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F744628\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F744629\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F744650\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16324123\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F854891\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F744645\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9008\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9008|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?29/43/30389?source=related_link\">",
"      Ibuprofen, pseudoephedrine, and chlorpheniramine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_40_10889="Normal upper airway MRI";
var content_f10_40_10889=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F79199%7EPULM%2F50443&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F79199%7EPULM%2F50443&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mid-sagittal MRI in a normal subject highlighting the four upper airway regions",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 442px; height: 344px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A) Nasopharynx which is defined from the nasal turbinates to the hard palate; B) retropalatal (RP) oropharynx extending from the hard palate to the caudal margin of the soft palate, C) retroglossal (RG) region from the caudal margin of the soft palate to the base of the epiglottis; and D) hypopharynx which is defined from the base of the tongue to the larynx.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Richard J Schwab, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 556px\">",
"   <div class=\"ttl\">",
"    Normal retropalatal anatomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 536px; height: 357px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Axial spin echo MRI in a normal subject in the retropalatal region. The tongue, soft palate, parapharyngeal fat pads, lateral parapharyngeal walls, parotid gland, subcutaneous fat, teeth, and mandibular rami are all highlighted on this image.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Schwab, RJ, Gupta, KB, Gefter, WB, et al. Upper airway and soft tissue anatomy in normal subjects and patients with sleep-disordered breathing. Significance of the lateral pharyngeal walls. Am J Respir Crit Care Med 1995; 152:1673. Official journal of the American Thoracic Society. Copyright &copy;1995 American Thoracic Society.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_40_10889=[""].join("\n");
var outline_f10_40_10889=null;
var title_f10_40_10890="Methylphenidate: Pediatric drug information";
var content_f10_40_10890=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Methylphenidate: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?38/60/39881?source=see_link\">",
"    see \"Methylphenidate: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?7/43/7863?source=see_link\">",
"    see \"Methylphenidate: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709144\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F195295\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Concerta&reg;;",
"     </li>",
"     <li>",
"      Daytrana&reg;;",
"     </li>",
"     <li>",
"      Metadate CD&reg;;",
"     </li>",
"     <li>",
"      Metadate&reg; ER;",
"     </li>",
"     <li>",
"      Methylin&reg;;",
"     </li>",
"     <li>",
"      Quillivant&trade; XR;",
"     </li>",
"     <li>",
"      Ritalin LA&reg;;",
"     </li>",
"     <li>",
"      Ritalin-SR&reg;;",
"     </li>",
"     <li>",
"      Ritalin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F195296\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Methylphenidate&reg;;",
"     </li>",
"     <li>",
"      Apo-Methylphenidate&reg; SR;",
"     </li>",
"     <li>",
"      Biphentin&reg;;",
"     </li>",
"     <li>",
"      Concerta&reg;;",
"     </li>",
"     <li>",
"      PHL-Methylphenidate;",
"     </li>",
"     <li>",
"      PMS-Methylphenidate;",
"     </li>",
"     <li>",
"      ratio-Methylphenidate;",
"     </li>",
"     <li>",
"      Ritalin&reg;;",
"     </li>",
"     <li>",
"      Ritalin&reg; SR;",
"     </li>",
"     <li>",
"      Sandoz-Methylphenidate SR;",
"     </li>",
"     <li>",
"      Teva-Methylphenidate ER-C",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1053970\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Central Nervous System Stimulant",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1053963\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?38/60/39881?source=see_link\">",
"      see \"Methylphenidate: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Discontinue medication if no improvement is seen after appropriate dosage adjustment over a 1-month period of time:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Children and Adolescents:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Attention-deficit/hyperactivity disorder:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Immediate release products (eg, Methylin&reg;, Ritalin&reg;):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     Children &ge;3-5 years, moderate to severe dysfunction: Limited data available;  AAP considers first-line agent in this patient population (AAP, 2011): Initial: 1.25 mg twice daily; titrate to effect over 1-4 weeks; usual reported daily range: 3.75-30 mg/day divided into two or three daily doses (Ghuman, 2008; Greenhill, 2006). In the largest trial, a multicenter, randomized, placebo-controlled, crossover study of 165 preschool children (age range: 3-5.5 years), statistically and clinically significant improvements in ADHD scores were reported with doses of 2.5 mg, 5 mg, and 7.5 mg 3 times daily; in some patients [n=7 (4%)], dose titration to 10 mg 3 times daily was necessary; the mean effective total daily dose: 14.2 &plusmn; 8.1 mg/",
"     <b>",
"      day",
"     </b>",
"     . With this younger patient population, the effect size was smaller than that seen in school-age children (Greenhill, 2006).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     Children &ge;6 years and Adolescents: Initial: 0.3 mg/kg/dose or 2.5-5 mg/dose given before breakfast and lunch; increase by 0.1 mg/kg/dose or by 5-10 mg/day at weekly intervals; usual dose: 0.3-1 mg/kg/day or 20-30 mg/",
"     <b>",
"      day",
"     </b>",
"     in 2-3 divided doses; maximum daily dose dependent upon patient weight: 2 mg/kg/day or if patient weight &le;50 kg: 60 mg/",
"     <b>",
"      day",
"     </b>",
"     ; in patients &gt;50 kg: 100 mg/day (Dopheide, 2009, Pliszka, 2007); most patients may require 3 doses/day (ie, additional dose at 4 PM)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Extended release, sustained release and long acting products:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     Metadate&reg; ER, Ritalin-SR&reg;: Children &ge;6 years and Adolescents: Sustained release and extended release tablets (duration of action ~8 hours) may be given in place of regular tablets, once the daily dose is titrated using the immediate release products and the titrated 8-hour dosage corresponds to sustained/extended release tablet size; Ritalin SR&reg; may be administered once or twice daily (AAP, 2011). Maximum daily dose is dependent upon patient weight: &le;50 kg: 60 mg/",
"     <b>",
"      day",
"     </b>",
"     ;  &gt;50 kg: 100 mg/",
"     <b>",
"      day",
"     </b>",
"     (Dopheide, 2009; Pliszka, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     Concerta&reg;: Children &ge;6 years and Adolescents:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;\">",
"     <i>",
"      Methylphenidate-naive patients:",
"     </i>",
"     Initial: 18 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;\">",
"     <i>",
"      Patients currently using immediate release methylphenidate:",
"     </i>",
"     Initial dose: Dosing based on current regimen and clinical judgment; suggested dosing listed below:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:14em;text-align:justify;\">",
"     Switching from methylphenidate immediate release 5 mg 2-3 times daily: Concerta&reg; 18 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:14em;text-align:justify;\">",
"     Switching from methylphenidate immediate release 10 mg 2-3 times daily: Concerta&reg; 36 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:14em;text-align:justify;\">",
"     Switching from methylphenidate immediate release 15 mg 2-3 times daily: Concerta&reg; 54 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:14em;text-align:justify;\">",
"     Switching from methylphenidate immediate release 20 mg 2-3 times daily: Concerta&reg; 72 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;text-align:justify;\">",
"     <i>",
"      Dosage adjustment:",
"     </i>",
"     May increase by Concerta&reg; 18 mg/day increments at weekly intervals.",
"     <b>",
"      Note:",
"     </b>",
"     A dosage strength of 27 mg is available for situations in which a dosage between 18-36 mg is desired.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;text-align:justify;\">",
"     Maximum daily dose:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:14em;text-align:justify;\">",
"     Children 6-12 years: 54 mg/day; for patients &gt;50 kg, higher maximum daily doses may be considered (108 mg/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:14em;text-align:justify;\">",
"     Adolescents:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:16em;text-align:justify;\">",
"     &le;50 kg: 72 mg/day; not to exceed ~2 mg/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:16em;text-align:justify;\">",
"     &gt;50 kg:108 mg/day (Dopheide, 2009; Pliszka, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     Metadate CD&reg;: Children &ge;6 years and Adolescents: Initial: 20 mg once daily; may increase by 10-20 mg/day increments at weekly intervals; maximum daily dose dependent upon patient weight: &le;50 kg: 60 mg/",
"     <b>",
"      day",
"     </b>",
"     ;  &gt;50 kg: 100 mg/",
"     <b>",
"      day",
"     </b>",
"     (Dopheide, 2009; Pliszka, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     Quillivant&trade; XR: Children 6-12 years:  Initial: 20 mg once daily; may increase by 10-20 mg/day increments at weekly intervals; maximum daily dose: 60 mg/",
"     <b>",
"      day",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     Ritalin LA&reg;: Children &ge;6 years and Adolescents:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;text-align:justify;\">",
"     <i>",
"      Methylphenidate-naive patients:",
"     </i>",
"     Initial: 20 mg once daily; may increase by 10 mg/day increments at weekly intervals; maximum daily dose dependent upon patient weight: &le;50 kg: 60 mg/",
"     <b>",
"      day",
"     </b>",
"     ; &gt;50 kg: 100 mg/",
"     <b>",
"      day",
"     </b>",
"     (Dopheide, 2009; Pliszka, 2007).",
"     <b>",
"      Note:",
"     </b>",
"     If a lower initial dose is desired, patients may begin with Ritalin LA&reg; 10 mg once daily. Alternatively, patients may begin therapy with an immediate release product, and switch to Ritalin LA&reg; once immediate release dosage is titrated to 5 mg twice daily (see below)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;text-align:justify;\">",
"     <i>",
"      Patients currently receiving  immediate release methylphenidate:",
"     </i>",
"     Initial dose: Dosing based on current regimen and clinical judgment; suggested dosing listed below:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:14em;text-align:justify;\">",
"     Switching from methylphenidate immediate release 5 mg twice daily: Ritalin LA&reg; 10 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:14em;text-align:justify;\">",
"     Switching from methylphenidate immediate release 10 mg twice daily: Ritalin LA&reg; 20 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:14em;text-align:justify;\">",
"     Switching from methylphenidate immediate release 15 mg twice daily: Ritalin LA&reg; 30 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:14em;text-align:justify;\">",
"     Switching from methylphenidate immediate release 20 mg twice daily: Ritalin LA&reg; 40 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:14em;text-align:justify;\">",
"     Switching from methylphenidate immediate release 30 mg twice daily: Ritalin LA&reg; 60 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;text-align:justify;\">",
"     <i>",
"      Patients currently receiving methylphenidate sustained release (SR):",
"     </i>",
"     The same total daily dose of Ritalin LA&reg; should be used.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;text-align:justify;\">",
"     <i>",
"      Dosage adjustment:",
"     </i>",
"     May increase Ritalin LA&reg;: by 10 mg/day increments at weekly intervals",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;text-align:justify;\">",
"     Maximum daily dose: Dependent upon patient weight: &le;50 kg: 60 mg/",
"     <b>",
"      day",
"     </b>",
"     ; &gt;50 kg: 100 mg/",
"     <b>",
"      day",
"     </b>",
"     (Dopheide, 2009; Pliszka, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Topical: Transdermal patch (Daytrana&reg;): Children and Adolescents 6-17 years: Initial: 10 mg (12.5 cm",
"     <sup>",
"      2",
"     </sup>",
"     ) patch once daily; apply to hip 2 hours before effect is needed and remove 9 hours after application; titrate dose based on response and tolerability; may increase to next transdermal patch dosage size no more frequently than every week. Patch may be removed before 9 hours if a shorter duration of action is required or if late day adverse effects appear. Plasma concentrations usually start to decline when the patch is removed but drug absorption may continue for several hours after patch removal.",
"     <b>",
"      Note:",
"     </b>",
"     The manufacturer&rsquo;s labeling recommends patients converting from another formulation of methylphenidate to the transdermal patch should be initiated at 10 mg regardless of their previous dose and titrated as needed due to the differences in bioavailability of the transdermal formulation. However, some clinicians have supported higher starting patch doses for patients converting from oral methylphenidate doses of &gt;20 mg/day; for example, the 15 mg (18.75 cm",
"     <sup>",
"      2",
"     </sup>",
"     ) patch has been investigated to have the same dose equivalency as 7.5 mg given 3 times daily (22.5 mg/day) of the immediate release oral formulation (Arnold, 2007).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Narcolepsy:",
"     </b>",
"     Children &ge;6 years and Adolescents: Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Immediate release tablets and oral solution (Methylin&reg;, Ritalin&reg;): Initial: 5 mg twice daily given before breakfast and lunch; increase by 5-10 mg/day at weekly intervals; 2-3 times per day; maximum daily dose: 60 mg/",
"     <b>",
"      day",
"     </b>",
"     (in 2-3 divided doses)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Extended/sustained release tablets (Metadate&reg; ER, Ritalin-SR&reg;): May be given in place of immediate release products (duration of action: ~8 hours), once the immediate release formulation daily dose is titrated and the titrated 8-hour dosage corresponds to sustained or extended release tablet size; maximum daily dose: 60 mg/",
"     <b>",
"      day",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Attention-deficit/hyperactivity disorder:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Immediate release (IR) products (tablets, chewable tablets, and solution): Initial: 5 mg twice daily, before breakfast and lunch; increase by 5-10 mg daily at weekly intervals; maximum dose: 60 mg daily (in 2-3 divided doses)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Extended release (ER), sustained release (SR) products (capsules, tablets, and oral suspension):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Concerta&reg;: Adults &lt;65 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     Patients not currently taking methylphenidate: Initial dose: 18-36 mg once every morning",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     Patients currently taking methylphenidate:",
"     <b>",
"      Note:",
"     </b>",
"     Initial dose: Dosing based on current regimen and clinical judgment; suggested dosing listed below:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;\">",
"     Switching from methylphenidate 5 mg 2-3 times daily: 18 mg once every morning",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;\">",
"     Switching from methylphenidate 10 mg 2-3 times daily: 36 mg once every morning",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;\">",
"     Switching from methylphenidate 15 mg 2-3 times daily: 54 mg once every morning",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;\">",
"     Switching from methylphenidate 20 mg 2-3 times daily: 72 mg once every morning",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     Dose adjustment: May increase dose in increments of 18 mg; dose may be adjusted at weekly intervals. A dosage strength of 27 mg is available for situations in which a dosage between 18-36 mg is desired; maximum dose: 72 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Metadate&reg; ER, Ritalin-SR&reg;: May be given in place of immediate release products, once the daily dose is titrated and the titrated 8-hour dosage corresponds to sustained or extended release tablet size; maximum: 60 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Metadate CD&reg;, Quillivant&trade; XR : Initial: 20 mg once daily; may be adjusted in 10-20 mg increments at weekly intervals; maximum: 60 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Ritalin LA&reg;: Initial: 20 mg once daily (l0 mg once daily may be considered for some patients); may be adjusted in 10 mg increments at weekly intervals; maximum: 60 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Conversion from immediate release or sustained release methylphenidate formulation to Ritalin LA&reg;: Use equivalent total daily dose administered once daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Narcolepsy:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Immediate release tablets and solution (Methylin&reg;, Ritalin&reg;): Initial: 5 mg twice daily before breakfast and lunch; increase by 5-10 mg daily at weekly intervals; 10 mg 2-3 times per day; maximum daily dose: 60 mg/day (in 2-3 divided doses).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Extended/sustained release tablets (Metadate&reg; ER, Ritalin-SR&reg;): May be given in place of immediate release products (duration of action: ~8 hours), once the immediate release formulation daily dose is titrated and the titrated 8-hour dosage corresponds to sustained or extended release tablet size; maximum: 60 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosing adjustment for renal impairment:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Oral: No dosage adjustment provided in manufacturer&rsquo;s labeling (has not been studied); undergoes extensive metabolism to a renally eliminated metabolite with little or no pharmacologic activity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Transdermal: No dosage adjustment provided in manufacturer&rsquo;s labeling (has not been studied).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosing adjustment for hepatic impairment:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Oral: No dosage adjustment provided in manufacturer&rsquo;s labeling (has not been studied).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Transdermal: No dosage adjustment provided in manufacturer&rsquo;s labeling (has not been studied).",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F195272\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, extended release, oral, as hydrochloride [bi-modal release]: 10 mg [generic for Metadate CD&reg;], 20 mg [generic for Metadate CD&reg;], 20 mg [generic for Ritalin LA&reg;], 30 mg [generic for Metadate CD&reg;], 30 mg [generic for Ritalin LA&reg;], 40 mg [generic for Metadate CD&reg;], 40 mg [generic for Ritalin LA&reg;], 50 mg [generic for Metadate CD&reg;], 60 mg [generic for Metadate CD&reg;]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Metadate CD&reg;: 10 mg [contains sucrose; 3 mg immediate release, 7 mg extended release]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Metadate CD&reg;: 20 mg [contains sucrose; 6 mg immediate release, 14 mg extended release]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Metadate CD&reg;: 30 mg [contains sucrose; 9 mg immediate release, 21 mg extended release]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Metadate CD&reg;: 40 mg [contains sucrose; 12 mg immediate release, 28 mg extended release]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Metadate CD&reg;: 50 mg [contains sucrose; 15 mg immediate release, 35 mg extended release]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Metadate CD&reg;: 60 mg [contains sucrose; 18 mg immediate release, 42 mg extended release]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ritalin LA&reg;: 10 mg [5 mg immediate release, 5 mg extended release]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ritalin LA&reg;: 20 mg [10 mg immediate release, 10 mg extended release]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ritalin LA&reg;: 30 mg [15 mg immediate release, 15 mg extended release]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ritalin LA&reg;: 40 mg [20 mg immediate release, 20 mg extended release]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Patch, transdermal:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Daytrana&reg;: 10 mg/9 hours (30s) [12.5 cm",
"     <sup>",
"      2",
"     </sup>",
"     , total methylphenidate 27.5 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Daytrana&reg;: 15 mg/9 hours (30s) [18.75 cm",
"     <sup>",
"      2",
"     </sup>",
"     , total methylphenidate 41.3 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Daytrana&reg;: 20 mg/9 hours (30s) [25 cm",
"     <sup>",
"      2",
"     </sup>",
"     , total methylphenidate 55 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Daytrana&reg;: 30 mg/9 hours (30s) [37.5 cm",
"     <sup>",
"      2",
"     </sup>",
"     , total methylphenidate 82.5 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder for suspension, extended release, oral, as hydrochloride [bi-modal release]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Quillivant&trade; XR: 25 mg/5 mL (60 mL, 120 mL, 150 mL, 180 mL) [contains sodium benzoate; banana flavor; 5 mg immediate release, 20 mg extended release]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral, as hydrochloride: 5 mg/5 mL (500 mL); 10 mg/mL (500 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Methylin&reg;: 5 mg/5 mL (500 mL); 10 mg/5 mL (500 mL) [grape flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as hydrochloride: 5 mg, 10 mg, 20 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ritalin&reg;: 5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ritalin&reg;: 10 mg, 20 mg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, chewable, oral, as hydrochloride:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Methylin&reg;: 2.5 mg [contains phenylalanine 0.42 mg/tablet; grape flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Methylin&reg;: 5 mg [contains phenylalanine 0.84 mg/tablet; grape flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Methylin&reg;: 10 mg [scored; contains phenylalanine 1.68 mg/tablet; grape flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, extended release, oral, as hydrochloride: 10 mg, 20 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Metadate&reg; ER: 20 mg [contains lactose]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, extended release, oral, as hydrochloride [bi-modal release]: 18 mg, 27 mg, 36 mg, 54 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Concerta&reg;: 18 mg [4 mg immediate release, 14 mg extended release]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Concerta&reg;: 27 mg [6 mg immediate release, 21 mg extended release]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Concerta&reg;: 36 mg [8 mg immediate release, 28 mg extended release]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Concerta&reg;: 54 mg [12 mg immediate release, 42 mg extended release]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, sustained release, oral, as hydrochloride: 20 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ritalin-SR&reg;: 20 mg [dye free]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F195256\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Extended release capsule, extended/sustained release tablet, immediate release tablet, immediate release oral solution",
"    </p>",
"   </div>",
"   <div class=\"block csi drugH1Div\" id=\"F195330\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Controlled Substance",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C-II",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874704\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Concerta&reg;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088575.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088575.pdf",
"     </a>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Daytrana&reg;:",
"     <a href=\"file://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021514s009s010MedGuide.pdf\" target=\"_blank\">",
"      file://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021514s009s010MedGuide.pdf",
"     </a>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Metadate CD&reg;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088635.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088635.pdf",
"     </a>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Methylin&reg; chewable tablet:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088639.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088639.pdf",
"     </a>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Methylin&reg;  immediate release oral solution:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088640.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088640.pdf",
"     </a>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Quillivant&trade; XR extended release oral suspension:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM322209.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM322209.pdf",
"     </a>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Ritalin&reg;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm089090.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm089090.pdf",
"     </a>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Ritalin LA&reg;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm089092.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm089092.pdf",
"     </a>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Ritalin-SR&reg;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm089095.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm089826.pdf",
"     </a>",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1053974\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: To avoid insomnia, last daily dose should be administered several hours before retiring.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Immediate release formulations:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Tablet (Ritalin&reg;), oral solution (Methylin&reg;): Administer on an empty stomach ~30-45 minutes before meals. Ensure last daily dose is administered before 6 PM if difficulty sleeping occurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Chewable tablet (Methylin&reg;): Administer on an empty stomach ~30-45 minutes before meals with at least 8 ounces of water or other fluid; choking may occur if not enough fluids are taken. Ensure last daily dose is administered before 6 PM if difficulty sleeping occurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Extended/sustained release formulations:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Tablets:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Metadate ER&reg;:  May be taken with or without food. Swallow whole; do not crush, chew, or break tablets.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Ritalin SR&reg;:  Administer 30-45 minutes before a meal. Swallow whole; do not crush, chew, or break tablets.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Concerta&reg;: May be administered without regard to food, but must be taken with water, milk, or juice; administer dose once daily in the morning; do not crush, chew, or divide tablets",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Capsules:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Metadate CD&reg;: Administer dose once daily in the morning, before breakfast, with water, milk, or juice; capsule may be swallowed whole or opened and contents sprinkled on a small amount (one tablespoonful) of applesauce; immediately consume drug/applesauce mixture; do not store for future use; swallow applesauce without chewing; do not crush or chew capsule contents; drink fluids after consuming drug/applesauce mixture to ensure complete swallowing of beads; do not crush, chew, or divide capsules or its contents",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Ritalin LA&reg;: Administer dose once daily in the morning; may be administered with or without food (but some food may delay absorption); capsule may be swallowed whole or may be opened and contents sprinkled on a small amount (one spoonful) of applesauce.",
"     <b>",
"      Note:",
"     </b>",
"     Applesauce should not be warm; immediately consume drug/applesauce mixture; do not store for future use; do not crush, chew, or divide capsule or its contents.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Powder for oral suspension (Quillivant&trade; XR): Administer in the morning with or without food. Shake bottle &ge;10 seconds prior to administration. Use the oral dosing dispenser provided; wash after each use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Topical: Transdermal (Daytrana&reg;): Apply patch immediately after opening pouch and removing protective liner; do not use patch if pouch seal is broken; do not cut patch; do not use patches that are cut or damaged. If difficulty is experienced when separating the patch from the liner or if any medication (sticky substance) remains on the liner after separation, discard that patch and apply a new patch. Apply to clean, dry, healthy skin on the hip; do not apply to oily, damaged, or irritated skin; do not apply to the waistline; do not premedicate the patch site with hydrocortisone or other solutions, creams, ointments, or emollients. Apply at the same time each day, 2 hours before effect is needed. Alternate site of application daily (ie, use alternate hip). Press patch firmly for 30 seconds to ensure proper adherence. Remove patch 9 hours after application. Patch may be removed earlier if a shorter duration of action is required or if late day adverse effects occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Avoid exposure of application site to external heat source (eg, hair dryers, electric blankets, heating pads, heated water beds), which may significantly increase the rate and amount of drug absorbed. Exposure of patch to water during swimming, bathing, or showering may affect patch adherence. Do not reapply patch with dressings, tape, or other adhesives. If patch should become dislodged, may replace with new patch (to different site) but total wear time should not exceed 9 hours.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     During removal, peel off patch slowly. If needed, patch removal may be helped by applying an oil-based product (ie, mineral oil, olive oil, or petroleum jelly) to the patch edges, gently working it underneath the patch edges. If a patch is not able to be removed, contact a physician or pharmacist. Nonmedical adhesive removers and acetone-based products, such as nail polish remover, should not be used to remove patches or adhesive. If adhesive residue remains on child&rsquo;s skin after patch removal, use an oil-based product and gently rub area to remove adhesive. Avoid touching the sticky side of the patch. Wash hands with soap and water after handling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dispose of used patch by folding adhesive side onto itself, and discard in toilet or appropriate lidded container; discard unused patches that are no longer needed in the same manner; protective pouch and liner should be discarded in an appropriate lidded container.",
"     <b>",
"      Note:",
"     </b>",
"     Used patches contain residual drug; keep all transdermal patches out of the reach of children.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1053966\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Immediate release formulations:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Chewable tablet: Store at controlled room temperature of 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); protect from moisture.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Oral solution: Chewable: Store at controlled room temperature of 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); protect from moisture.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Tablet: (Ritalin&reg;): Store at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F); protect from light.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Extended and sustained  release formulations:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Capsule (Metadate CD&reg;, Ritalin LA&reg;): Store at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Tablet:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Concerta&reg;: Store at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F); protect from humidity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Metadate&reg; ER: Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F); protect from moisture.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Powder for oral suspension (Quillivant&trade; XR): Store at 25&deg;C (77&deg;F), excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F) before and after reconstitution. Once reconstituted, bottle must be used within 4 months; dispense in original container.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Transdermal system (Daytrana&reg;): Store at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Keep patches stored in protective pouch. Once sealed tray or outer pouch is opened, use patches within 2 months; once an individual patch has been removed from the pouch and the protective liner removed, use immediately. Do not refrigerate or freeze.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1053973\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Concerta&reg;: Treatment of attention-deficit/hyperactivity disorder (ADHD) (FDA approved in ages 6-65 years)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Ritalin LA&reg;, Quillivant&trade; XR: Treatment of ADHD (FDA approved in ages 6-12 years)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Metadate CD&reg;: Treatment of ADHD (FDA approved in ages 6-15 years)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Metadate&reg; ER, Methylin&reg;, Ritalin&reg;, Ritalin SR&reg;: Treatment of ADHD, treatment of narcolepsy (FDA approved in ages &ge;6 years and adults)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topical Patch: Daytrana&reg;: Treatment of ADHD (FDA approved in ages 6-17 years)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F195336\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Metadate CD&reg; may be confused with Metadate&reg; ER",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Metadate&reg; ER may be confused with methadone",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Methylphenidate may be confused with methadone",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Ritalin&reg; may be confused with Rifadin&reg;, ritodrine",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Ritalin LA&reg; may be confused with Ritalin-SR&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F195334\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      All dosage forms:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Angina, cardiac arrhythmia, cerebral arteritis, cerebral hemorrhage, cerebral occlusion, cerebrovascular accidents, hyper-/hypotension, MI, murmur, palpitation, pulse increased/decreased, Raynaud&rsquo;s phenomenon, tachycardia, vasculitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Aggression, agitation, anger, anxiety, confusional state, depression, dizziness, drowsiness, emotional lability, fatigue, fever, headache, hypervigilance, insomnia, irritability, lethargy, motion sickness (children), nervousness, neuroleptic malignant syndrome (NMS) (rare), restlessness, stroke, tension, tic (children), Tourette's syndrome (rare), toxic psychosis, tremor, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Alopecia, erythema multiforme, excoriation (children), exfoliative dermatitis, hyperhidrosis, rash, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Dysmenorrhea, growth retardation, libido decreased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, anorexia, appetite decreased, bruxism, constipation, diarrhea, dyspepsia, nausea, vomiting, weight loss, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Erectile dysfunction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Anemia, leukopenia, pancytopenia, thrombocytopenia, thrombocytopenic purpura",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Bilirubin increased, hepatic coma, liver function tests abnormal, transaminases increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, dyskinesia, muscle tightness, paresthesia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blurred vision, dry eyes, eye pain (children), mydriasis, visual accommodation disturbance",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Necrotizing vasculitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Cough increased, dyspnea, pharyngitis, pharyngolaryngeal pain, rhinitis, sinusitis, upper respiratory tract infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Accidental injury, hypersensitivity reactions",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Alkaline phosphatase increased, bradycardia, disorientation, extrasystole, hallucinations; hypersensitivity reactions (eg, angioedema, anaphylactic reactions, auricular swelling, bullous conditions, exfoliative conditions, urticaria, pruritus, rash, eruptions, exanthemas); mania, migraine, obsessive-compulsive disorder, priapism, seizure, supraventricular tachycardia, ventricular extrasystole",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Transdermal system:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Dizziness, emotional instability, headache, insomnia, irritability, tic",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, anorexia, appetite decreased, nausea, vomiting, weight loss",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Application site reaction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Nasal congestion, nasopharyngitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Viral infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Allergic contact dermatitis/sensitization, anaphylaxis, angioedema, dyskinesia, hallucinations, seizures",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1053978\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to methylphenidate or any component; glaucoma; motor tics; Tourette's syndrome (diagnosis or family history); patients with marked agitation, tension, and anxiety; use with or within 14 days following MAO inhibitor therapy (hypertensive crisis may occur)",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Metadate CD&reg;  and Metadate ER&reg; are also contraindicated in patients with severe hypertension, heart failure, arrhythmia, hyperthyroidism, thyrotoxicosis, recent MI, or angina and concomitant use of halogenated anesthetics.",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1053962\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with heart failure, recent MI, hyperthyroidism, seizures, acute stress reactions, emotional instability, or history of substance abuse. Hematological monitoring is advised with long term use. Rare cases of neuroleptic malignant syndrome have been reported; usually in patients receiving concurrent mediations associated with the syndrome; one case reported with concurrent first dose of venlafaxine.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Use with caution in preschool age-children; clinical trials have shown children 3-5 years of age are more sensitive to methylphenidate adverse effects resulting in discontinuation of therapy compared to school-age children (discontinuation rate from trials: 11% vs &lt; 1 %) (Wigal, 2006). The moderate to severe adverse effect profiles in children are associated with age-related differences; in preschool children, the most commonly reported were crabbiness/irritability, emotional outbursts, difficulty falling asleep, repetitive behavior/thoughts,  and decreased appetite; in school-age chidren, they were decreased appetite, delay of sleep onset, headache, and stomach ache (Wigal, 2006).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Chewable tablets contain aspartame which is metabolized to phenylalanine and must be avoided (or used with caution) in patients with phenylketonuria. Chewable tablets must be taken with adequate amount of liquid, otherwise tablet may swell and block the throat or esophagus and cause choking; do not use chewable tablets in patients who have difficulty swallowing; instruct patients to seek immediate medical attention if chest pain, vomiting, difficulty in breathing or swallowing occur after taking chewable tablet.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Metadate CD&reg; contains sucrose; avoid use in hereditary problems of fructose intolerance, sucrase-isomaltose insufficiency, and glucose-galactose malabsorption. Metadate&reg; ER contains lactose; avoid in hereditary problems of galactose intolerance, glucose-galactose malabsorption, and the Lapp lactase deficiency. Concomitant use of Metadate&reg; CD or Metadate&reg; ER with halogenated anesthetics is contraindicated; use may cause sudden elevations in blood pressure; if surgery is planned, do not administer Metadate&reg; CD or Metadate&reg; ER on day of surgery.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1053961\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serious cardiovascular events including sudden death may occur in patients with pre-existing structural cardiac abnormalities or other serious heart problems. Sudden death has been reported in children and adolescents; sudden death, stroke, and MI have been reported in adults. Avoid the use of CNS stimulants in patients with known serious structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities, coronary artery disease, or other serious cardiac problems that could place patients at an increased risk to the sympathomimetic effects of CNS stimulants. Patients should be carefully evaluated for cardiac disease prior to initiation of therapy. If a child displays symptoms of cardiovascular disease, including chest pain, dyspnea, or fainting, parents should seek immediate medical care for the child.",
"     <b>",
"      Note:",
"     </b>",
"     The American Heart Association recommends that all children diagnosed with ADHD who may be candidates for medication, such as methylphenidate, should have a thorough cardiovascular assessment prior to initiation of therapy. This assessment should include a combination of medical history, family history, and physical examination focusing on cardiovascular disease risk factors. An ECG is not mandatory but should be considered.",
"     <b>",
"      Note:",
"     </b>",
"     In a recent retrospective study on the possible association between stimulant medication use and sudden death in children, 564 previously healthy children who died suddenly in motor vehicle accidents were compared to a group of 564 previously healthy children who died suddenly. Two of the 564 (0.4%) children in motor vehicle accidents were taking stimulant medications compared to 10 of 564 (1.8%) children who died suddenly. While the authors of this study conclude there may be an association between stimulant use and sudden death in children, there were a number of limitations to the study and the FDA cannot conclude this information impacts the overall risk:benefit profile of these medications (Gould, 2009).",
"     <b>",
"      Note:",
"     </b>",
"     In a large retrospective cohort study involving 1,200,438 children and young adults (age: 2-24 years), none of the currently available stimulant medications or atomoxetine were shown to increase the risk of serious cardiovascular events (ie, acute MI, sudden cardiac death, or stroke) in current (adjusted hazard ratio: 0.75; 95% CI: 0.31-1.85) or former (adjusted hazard ratio: 1.03; 95% CI: 0.57-1.89) users compared to nonusers (Cooper, 2011). It should be noted that due to the upper limit of the 95% CI, the study could not rule out a doubling of the risk, albeit low.",
"     <b>",
"      Note:",
"     </b>",
"     ECG abnormalities and 4 cases of sudden cardiac death have been reported in children receiving clonidine with methylphenidate; reduce dose of methylphenidate by 40% when used concurrently with clonidine; consider ECG monitoring.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Stimulant medications may increase blood pressure (average increase 2-4 mm Hg) and heart rate (average increase 3-6 bpm); some patients may experience greater increases; use stimulant medications with caution in patients with hypertension and other cardiovascular conditions that may be exacerbated by increases in blood pressure or heart rate. Metadate CD&reg; and Metadate ER&reg; use is contraindicated in patients with severe hypertension.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Psychiatric  adverse events may occur. Stimulants may exacerbate symptoms of behavior disturbance and thought disorder in patients with pre-existing psychosis. New-onset psychosis or mania may occur with stimulant use in patients with pre-existing psychosis. New-onset psychosis or mania may occur with stimulant use in patients without a prior history of psychotic illness or mania, even at standard doses. May induce mixed/manic episode in patients with bipolar disorder; patients should be screened for bipolar disorder prior to treatment; consider discontinuation if such symptoms (eg, delusional thinking, hallucinations, or mania) occur. May be associated with aggressive behavior or hostility (causal relationship not established); monitor for development or worsening of these behaviors).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Potential for drug dependency exists",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; prolonged administration may lead to drug dependence; abrupt discontinuation following high doses or for prolonged periods may result in symptoms of withdrawal; avoid abrupt discontinuation in patients who have received methylphenidate for prolonged periods. Do not use for severe depression or normal fatigue states. CNS stimulants possess a high potential for abuse",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; assess risk of abuse prior to initiating therapy and continue to monitor for signs of abuse throughout therapy; misuse may cause sudden death and serious cardiovascular adverse events; use with caution in patients with history of ethanol or drug abuse.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Long-term effects in pediatric patients have not been determined. Use of stimulants in children has been associated with growth suppression (monitor growth; treatment interruption may be needed). Appetite suppression may occur; monitor weight during therapy, particularly in children. Stimulants may lower seizure threshold leading to new onset or breakthrough seizure activity (use with caution in patients with a history of seizure disorder). Visual disturbances (difficulty in accommodation and blurred vision) have been reported.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     A potential for GI obstruction exists with Concerta&reg; (tablet is nondeformable); do not ordinarily use in patients with severe GI narrowing (eg, esophageal motility disorders, small bowel inflammatory disease, short gut syndrome, history of cystic fibrosis, peritonitis, chronic intestinal pseudo-obstruction, or Meckel's diverticulum).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Transdermal system (Daytrana&reg;) may cause allergic contact sensitization, characterized by intense local reactions (edema, vesicles, papules) that may spread beyond the patch site; remove patch and monitor application site if reaction occurs; seek further evaluation if erythema, edema, and/or papules do not significantly decrease or resolve within 24 hours of patch removal. Allergic sensitization may subsequently manifest systemically when methylphenidate is administered orally or via other routes; systemic sensitization reactions may include dermatitis, generalized skin eruptions, headache, fever, vomiting, diarrhea, arthralgia, or malaise; initiate oral methylphenidate under close medical supervision in patients who have experienced a contact sensitization to the transdermal system; some of these patients may",
"     <b>",
"      not",
"     </b>",
"     be able to take methylphenidate in any dosage form. Do not expose transdermal application site to direct external heat sources (eg, electric blankets, heating pads, heated water beds), a &gt;2-fold increase in drug release may occur. Powder for oral suspension (Quillivant&trade; XR) contains benzyl alcohol which may cause allergic reactions in susceptible individuals.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F195323\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2D6 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F195265\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May increase the absorption of Methylphenidate. Specifically, antacids may interfere with the normal release of drug from the extended-release capsules (Ritalin LA brand), which could result in both increased absorption (early) and decreased delayed absorption.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: Methylphenidate may diminish the antihypertensive effect of Antihypertensives.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Minoxidil (Topical).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anti-Parkinson's Agents (Dopamine Agonist): Methylphenidate may enhance the adverse/toxic effect of Anti-Parkinson's Agents (Dopamine Agonist).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotics: May enhance the adverse/toxic effect of Methylphenidate. Methylphenidate may enhance the adverse/toxic effect of Antipsychotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cannabinoids: May enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloNIDine: Methylphenidate may enhance the adverse/toxic effect of CloNIDine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: Methylphenidate may increase the serum concentration of Fosphenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     H2-Antagonists: May increase the absorption of Methylphenidate. Specifically, H2-antagonists may interfere with the normal release of drug from the extended-release capsules (Ritalin LA brand), which could result in both increased absorption (early) and decreased delayed absorption.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Inhalational Anesthetics: Methylphenidate may enhance the hypertensive effect of Inhalational Anesthetics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Sympathomimetics may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ioflupane I 123: Methylphenidate may diminish the diagnostic effect of Ioflupane I 123.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the hypertensive effect of Methylphenidate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PHENobarbital: Methylphenidate may increase the serum concentration of PHENobarbital.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: Methylphenidate may increase the serum concentration of Phenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Primidone: Methylphenidate may increase serum concentrations of the active metabolite(s) of Primidone. Specifically, phenobarbital concentrations could become elevated. Methylphenidate may increase the serum concentration of Primidone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Proton Pump Inhibitors: May increase the absorption of Methylphenidate. Specifically, proton pump inhibitors may interfere with the normal release of drug from the extended-release capsules (Ritalin LA brand), which could result in both increased absorption (early) and decreased delayed absorption.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tricyclic Antidepressants: Methylphenidate may enhance the adverse/toxic effect of Tricyclic Antidepressants. Methylphenidate may increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Methylphenidate may increase the serum concentration of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1053981\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Immediate release (tablet, chewable tablet, solution): Food may increase oral absorption:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Concerta&reg;: A high-fat meal does not alter pharmacokinetics or pharmacodynamics; no evidence of dose dumping occurs when administered with or without food",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metadate CD&reg;: Food delays the early peak by &sim;1 hour; a high-fat meal increases peak concentrations by 30% and AUC by 17%; one adult study showed no difference in bioavailability when Metadate CD&reg; capsules were opened and contents sprinkled onto 1 tablespoon of applesauce (compared to fasting conditions; Pentikin, 2002).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Methylin&reg;:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Chewable tablets: A high-fat meal delays peak concentrations by &sim;1 hour, but increases AUC by &sim;20% (",
"     <b>",
"      Note:",
"     </b>",
"     Magnitude of food effect is similar to immediate release tablets).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral solution: A high-fat meal delays peak concentrations by &sim;1 hour, but increases peak by &sim;13% and AUC by &sim;25% (",
"     <b>",
"      Note:",
"     </b>",
"     Increase in peak concentration and AUC are similar to immediate release tablets).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Quillivant&trade; XR: A high-fat meal delays peak serum concentrations by ~1 hour, but increased peak by ~28% and AUC by ~19%; however, these changes are not considered to be clinically significant",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ritalin LA&reg;: Compared to fasting, food does not affect the first peak concentration, extent of absorption, or time to second peak concentration; however, the second peak was 25% lower. A high-fat meal delays absorption. Compared to fasting, no differences in pharmacokinetics occurred when Ritalin LA&reg; capsules were administered with applesauce. No evidence of dose dumping occurs when administered with or without food.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F195267\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F195281\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal studies have shown teratogenic effects to the fetus. There are no adequate and well-controlled studies in pregnant women. Do not use in women of childbearing age unless the potential benefit outweighs the possible risk.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1053969\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Evaluate patients for cardiac disease prior to initiation of therapy with thorough medical history, family history, and physical exam; consider ECG; perform ECG and echocardiogram if findings suggest cardiac disease; promptly conduct cardiac evaluation in patients who develop chest pain, unexplained syncope, or any other symptom of cardiac disease during treatment. Monitor CBC with differential, platelet count, liver enzymes, blood pressure, heart rate, height, weight, appetite, abnormal movements, growth in children. Patients should be re-evaluated at appropriate intervals to assess continued need of the medication. Observe for signs/symptoms of aggression or hostility, depression, delusional thinking, hallucinations, or mania. Monitor for visual disturbances. Monitor for signs of misuse, abuse, and addiction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Transdermal system: Also monitor the application site for local adverse reactions and allergic contact sensitization.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1053960\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Produces stimulant effect by activating the brain stem arousal system and cerebral cortex; blocks the reuptake of norepinephrine and dopamine into presynaptic neurons, thus increasing the concentrations of these neurotransmitters in the extraneuronal space.",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1053976\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action (AAP, 2011):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Immediate release formulations [chewable tablet, oral solution, tablet (Methylin&reg;, Ritalin&reg;)]: 20-60 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Extended release formulations [Capsule (Metadate CD&reg;, Ritalin LA&reg;), tablets (Concerta&reg;)]: 20-60 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Sustained release tablet (Ritalin-SR&reg;): 60-180 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Transdermal (Daytrana&reg;): 60 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Maximum effect: Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Immediate release tablet: Within 2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sustained release tablet: Within 4-7 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration of action (AAP, 2011):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Immediate release formulations [Chewable tablet, oral solution, immediate release tablet (Methylin&reg;, Ritalin&reg;)]: 3-5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Extended release capsule (Metadate CD&reg;, Ritalin LA&reg;): 6-8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Extended release tablet (Concerta&reg;): 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Sustained release tablet (Ritalin-SR&reg;):  2-6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Transdermal (Daytrana&reg;): 11-12 hours",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1053977\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Values reported below based on pediatric patient data or combined pediatric and adult data.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Immediate release products: Readily absorbed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Transdermal: Rate and extent of absorption is increased when applied to inflamed skin or exposed to heat; transdermal absorption may increase with chronic therapy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : d-methylphenidate: 2.65 &plusmn; 1.11 L/kg; l-methylphenidate: 1.80 &plusmn; 0.91 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 15%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic via hydroxylation (de-esterification by carboxylesterase CES1A1) to ritalinic acid (alpha-phenyl-2-piperidine acetic acid), which has little or no pharmacologic activity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Immediate release chewable tablets and oral solution: Bioequivalent to immediate release tablets",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Extended release suspension (Quillivant&trade; XR): 95% (relative to immediate release oral solution)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Transdermal patch (Daytrana&reg;): Lower first-pass effect compared to oral administration; thus, much lower doses (on a mg/kg basis) given via the transdermal route may still produce higher AUCs, compared to the oral route",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Immediate release formulations:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Chewable tablets, oral solution (Methylin&reg;): 3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Tablet (Ritalin&reg;):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     Children: 2.5 hours (range: 1.8-5.3 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     Adults: 3.5 hours (range: 1.3-7.7 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Extended release formulations:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Capsule:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     Metadate CD&reg;: 6.8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     Ritalin LA&reg;:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;text-align:justify;\">",
"     Children: 2.4 hours (range: 1.5-4 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;text-align:justify;\">",
"     Adults: 3.3 hours (range: 3-4.2 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Tablet (Concerta&reg;): 3.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Suspension (Quillivant&trade; XR): Children &ge;9 years, Adolescents, and Adults: ~5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Transdermal patch (Daytrana&reg;): Children and Adolescents 6-17 years: 4-5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Immediate release formulations:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Chewable tablets, oral solution (Methylin&reg;): 1-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Tablet (Ritalin&reg;): Children: 1.9 hours (range: 0.3-4.4 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Extended release formulations:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Capsule (Metadate CD&reg;): 1.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Tablet:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     Concerta&reg;: 6-10 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     Metadate ER&reg;: Children: 4.7 hours (range: 1.3-8.2 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Powder for oral suspension (Quillivant&trade; XR):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     Children (9-12 years): 4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     Adolescents (13-15 years): 2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     Adults: 4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Sustained release tablets (Ritalin SR&reg;): Children: 4.7 hours (range: 1.3-8.2 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Transdermal patch (Daytrana&reg;): Children 6-17 years: 8-10 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: 90% of dose is eliminated in the urine as metabolites and unchanged drug; main urinary metabolite (ritalinic acid) accounts for 80% of the dose; drug is also excreted in feces via bile",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1053968\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?7/43/7863?source=see_link\">",
"      see \"Methylphenidate: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Read the patient Medication Guide received with each prescription and refill of methylphenidate. Serious cardiac effects or psychiatric adverse effects may occur; notify physician of any heart problems, high blood pressure, or psychiatric conditions before starting therapy. May reduce the growth rate in children and has been associated with worsening of aggressive behavior; notify physician if child displays aggression or hostility; ensure physician monitors child&rsquo;s weight and height. Avoid caffeine and the herbal medicine St John's wort. May be habit-forming; avoid abrupt discontinuation after prolonged use. May cause dizziness or drowsiness and impair ability to perform activities requiring mental alertness or physical coordination. Notify physician if blurred vision occurs. Intact Concerta&reg; tablet shell may appear in stool (this is normal). Report the use of other medications and herbal or natural products to physician and pharmacist. Seek immediate medical attention if chest pain, vomiting, or difficulty in breathing or swallowing occurs after taking chewable tablet. When using transdermal patches, avoid exposing application site to external heat sources (eg, hair dryers, electric blankets, heating pads, heated water bed); patches may be irritating to the skin; inform physician if skin rash or irritation occurs; do not use patch if swelling or blistering occurs",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1053979\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Methylphenidate is a racemic mixture of d- and l-enantiomers; the d-enantiomer is more active than the l-enantiomer. Treatment with methylphenidate should include &ldquo;drug holidays&rdquo; or periodic discontinuation in order to assess the patient's requirements, decrease tolerance and limit suppression of linear growth and weight. Medications used to treat ADHD should be part of a total treatment program that may include other components such as psychological, educational, and social measures. Concerta&reg;, Metadate CD&reg;, and Ritalin LA&reg; are formulated to deliver methylphenidate in a biphasic release profile; Concerta&reg; is an osmotic controlled release formulation, with an immediate release (within 1 hour) outer coating; once daily Concerta&reg; has been shown to be as effective as immediate release methylphenidate tablets administered 3 times/day (Pelham, 2001). Metadate CD&reg; capsules contain both immediate release beads (30% of the dose) and extended release beads (70% of the dose). Ritalin LA&reg; capsules contain both immediate release beads (50% of the dose) and enteric coated, delayed release beads (50% of the dose). Methylin&reg; and Ritalin-SR&reg; tablets are color and additive free; Methylin&reg; oral solution is colorless. Concerta&reg; tablets may be seen on abdominal x-ray under certain conditions (eg, when digital enhancing techniques are used). Quillivant&trade; XR powder for oral suspension contains a combination of uncoated and coated ion exchange resin complex and a buffering solution based on the Oral XR + platform (Wigal, 2013). Once reconstituted with water forms an extended release suspension that contains approximately 20% immediate release and 80% extended release methylphenidate.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Daytrana&trade; Transdermal System consists of an adhesive-based matrix containing active drug which is dispersed in acrylic adhesive that is dispersed in a silicone adhesive. The patch consists of 3 layers: A polyester/ethylene vinyl acetate laminate (outside) film backing, the adhesive layer containing methylphenidate, and a flouropolymer-coated polyester protective liner (which must be removed before application). Long-term use of the transdermal system or Concerta &reg; &gt;7 weeks, Metadate&reg; CD &gt;3 weeks,  and Ritalin &reg; LA &gt;2 weeks have not been adequately studied; long-term usefulness should be periodically re-evaluated for the individual patient.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics, \"ADHD: Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2011, 128(5):1007-22.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics/American Heart Association Clarification of Statement on Cardiovascular Evaluation and Monitoring of Children and Adolescents With Heart Disease Receiving Medications for ADHD; available at: file://americanheart.mediaroon.com/index.php?s=43&amp;item=422.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics. Subcommittee on Attention-Deficit/Hyperactivity Disorder, &ldquo;Clinical Practice Guideline: Treatment of the School-Aged Child With Attention-Deficit/Hyperactivity Disorder,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(4):1033-44.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/40/10890/abstract-text/11581465/pubmed\" id=\"11581465\" target=\"_blank\">",
"        11581465",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Arnold LE, Lindsay RL, L&oacute;pez FA, et al, \"Treating Attention-Deficit/Hyperactivity Disorder With a Stimulant Transdermal Patch: The Clinical Art,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2007, 120(5):1100-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/40/10890/abstract-text/17974748/pubmed\" id=\"17974748\" target=\"_blank\">",
"        17974748",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cooper WO, Habel LA, Sox CM, et al, \"ADHD Drugs and Serious Cardiovascular Events in Children and Young Adults,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2011, 365(20):1896-904.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/40/10890/abstract-text/22043968/pubmed\" id=\"22043968\" target=\"_blank\">",
"        22043968",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ghuman JK, Arnold LE, and Anthony BJ, \"Psychopharmacological and Other Treatments in Preschool Children With Attention-Deficit/Hyperactivity Disorder: Current Evidence and Practice,\"",
"      <i>",
"       J Child Adolesc Psychopharmacol",
"      </i>",
"      , 2008, 18(5):413-47.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/40/10890/abstract-text/18844482/pubmed\" id=\"18844482\" target=\"_blank\">",
"        18844482",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gould MS, Walsh BT, Munfakh JL, et al, \"Sudden Death and Use of Stimulant Medications in Youths,\"",
"      <i>",
"       Am J Psychiatry",
"      </i>",
"      , 2009, 166(9):992-1001.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/40/10890/abstract-text/19528194/pubmed\" id=\"19528194\" target=\"_blank\">",
"        19528194",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Greenhill L, Kollins S, Abikoff H, et al, \"Efficacy and Safety of Immediate-Release Methylphenidate Treatment for Preschoolers With ADHD,\"",
"      <i>",
"       J Am Acad Child Adolesc Psychiatry",
"      </i>",
"      , 2006, 45(11):1284-93.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/40/10890/abstract-text/17023869/pubmed\" id=\"17023869\" target=\"_blank\">",
"        17023869",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Greenhill LL, &ldquo;Pharmacologic Treatment of Attention Deficit Hyperactivity Disorder,&rdquo;",
"      <i>",
"       Psychiatr Clin North Am",
"      </i>",
"      , 1992, 15(1):1-27.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/40/10890/abstract-text/1347936/pubmed\" id=\"1347936\" target=\"_blank\">",
"        1347936",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Greenhill LL, Pliszka S, Dulcan MK, et al, &ldquo;Practice Parameter for the Use of Stimulant Medications in the Treatment of Children, Adolescents, and Adults,&rdquo;",
"      <i>",
"       J Am Acad Child Adolesc Psychiatry",
"      </i>",
"      , 2002, 41(2 Suppl):26S-49S.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/40/10890/abstract-text/11833633/pubmed\" id=\"11833633\" target=\"_blank\">",
"        11833633",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hackett LP, Kristensen JH, Hale TW, et al, \"Methylphenidate and Breast-Feeding,\"",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2006, 40(10):1890-1.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/40/10890/abstract-text/16940409/pubmed\" id=\"16940409\" target=\"_blank\">",
"        16940409",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kelly DP and Aylward GP, &ldquo;Attention Deficits in School-Aged Children and Adolescents,&rdquo;",
"      <i>",
"       Pediatr Clin North Am",
"      </i>",
"      , 1992, 39(3):487-512.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/40/10890/abstract-text/ 1574355 /pubmed\" id=\" 1574355 \" target=\"_blank\">",
"        1574355",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pelham WE, Gnagy EM, Burrows-Maclean L, et al, &ldquo;Once-a-Day Concerta Methylphenidate Versus Three-Times-Daily Methylphenidate in Laboratory and Natural Settings,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 107(6), file://www.pediatrics.org/cgi/content/full/107/6/e105.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/40/10890/abstract-text/11389303 /pubmed\" id=\"11389303 \" target=\"_blank\">",
"        11389303",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pentikis HS, Simmons RD, Benedict MF, et al, &ldquo;Methylphenidate Bioavailability in Adults When an Extended-Release Multiparticulate Formulation is Administered Sprinkled on Food or as an Intact Capsule,&rdquo;",
"      <i>",
"       J Am Acad Child Adolesc Psychiatry",
"      </i>",
"      , 2002, 41(4):443-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/40/10890/abstract-text/11931601/pubmed\" id=\"11931601\" target=\"_blank\">",
"        11931601",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Spigset O, Brede WR, and Zahlsen K, \"Excretion of Methylphenidate in Breast Milk,\"",
"      <i>",
"       Am J Psychiatry",
"      </i>",
"      , 2007, 164(2):348.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/40/10890/abstract-text/17267805/pubmed\" id=\"17267805\" target=\"_blank\">",
"        17267805",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Vetter VL, Elia J, Erickson C, et al, \"Cardiovascular Monitoring of Children and Adolescents With Heart Disease Receiving Stimulant Drugs: A Scientific Statement From the American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee and the Council on Cardiovascular Nursing,\"",
"      <i>",
"       Circulation",
"      </i>",
"      , 2008, 117(18):2407-23.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/40/10890/abstract-text/18427125/pubmed\" id=\"18427125\" target=\"_blank\">",
"        18427125",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wigal SB, Childress AC, Belden HW, et al, \"NWP06, an Extended Release Oral Suspension of Methylphenidate, Improved Attention-Deficit/Hyperactivity Disorder Symptoms Compared With Placebo in a Laboratory Classroom Study,\"",
"      <i>",
"       J Child Adolesc Psychopharmacol",
"      </i>",
"      , January 5, 2013.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/40/10890/abstract-text/23289899/pubmed\" id=\"23289899\" target=\"_blank\">",
"        23289899",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wigal T, Greenhill L, Chuang S, et al, \"Safety and Tolerability of Methylphenidate in Preschool Children With ADHD,\"",
"      <i>",
"       J Am Acad Child Adolesc Psychiatry",
"      </i>",
"      , 2006, 45(11):1294-303.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/40/10890/abstract-text/17028508/pubmed\" id=\"17028508\" target=\"_blank\">",
"        17028508",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wilens TE and Biederman J, &ldquo;The Stimulants,&rdquo;",
"      <i>",
"       Psychiatr Clin North Am",
"      </i>",
"      , 1992, 15(1):191-222.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/40/10890/abstract-text/1347939/pubmed\" id=\"1347939\" target=\"_blank\">",
"        1347939",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12600 Version 42.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.55.141.10-6DAE62D42F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_40_10890=[""].join("\n");
var outline_f10_40_10890=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709144\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195295\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195296\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053970\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053963\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195272\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195256\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195330\">",
"      Controlled Substance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874704\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053974\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053966\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053973\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195336\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195334\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053978\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053962\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053961\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195323\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195265\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053981\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195267\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195281\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053969\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053960\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053976\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053977\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053968\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053979\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12600\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12600|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?38/60/39881?source=related_link\">",
"      Methylphenidate: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?7/43/7863?source=related_link\">",
"      Methylphenidate: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_40_10891="Drug induced diabetes";
var content_f10_40_10891=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F67257&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F67257&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Drugs that can impair glucose tolerance or cause overt diabetes mellitus",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Glucocorticoids",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Oral contraceptives",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tacrolimus, sirolimus,&nbsp;and cyclosporine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nicotinic acid (niacin)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        HIV protease inhibitors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thiazide diuretics (primarily at doses above 25 mg/day of hydrochlorothiazide or its equivalent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Atypical antipsychotics (clozapine, and some conventional antipsychotics)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gonadotropin releasing hormone agonists",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Other",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Beta blockers",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Clonidine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Pentamidine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Alcohol",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_40_10891=[""].join("\n");
var outline_f10_40_10891=null;
var title_f10_40_10892="Classification of jerk nystagmus";
var content_f10_40_10892=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F72446&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F72446&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Classification of jerk nystagmus",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Primary position",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Pure directions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Upbeat",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Downbeat",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Torsional",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Horizontal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Peripheral vestibular",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Congenital",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Periodic alternating",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Latent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Epileptic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Mixed directions (peripheral vestibular)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Horizontal/torsional",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Vertical/torsional",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Gaze-evoked",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gaze holding",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rebound",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Peripheral vestibular",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Brun's",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Positional",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Paroxysmal positional&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Posterior canalithiasis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Anterior canalithiasis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Horizontal canalithiasis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Static positional",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Dissociated",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Internuclear ophthalmoplegia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Other",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Convergence-retraction nystagmus",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_40_10892=[""].join("\n");
var outline_f10_40_10892=null;
var title_f10_40_10893="Oxygen carriers formerly under development";
var content_f10_40_10893=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F73791&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F73791&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Oxygen carriers - outcomes of products formerly under development in the US",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Type of compound",
"       </td>",
"       <td class=\"subtitle1\">",
"        Manufacturer",
"       </td>",
"       <td class=\"subtitle1\">",
"        Product name",
"       </td>",
"       <td class=\"subtitle1\">",
"        Status",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cross-linked Hgb",
"       </td>",
"       <td>",
"        Baxter Healthcare Corporation",
"       </td>",
"       <td>",
"        HemAssist",
"       </td>",
"       <td>",
"        Development halted",
"        <sup>",
"         [1]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Recombinant Hgb",
"       </td>",
"       <td>",
"        Baxter Healthcare Corporation",
"       </td>",
"       <td>",
"        <p>",
"         rHb1.1 (Optro)",
"        </p>",
"        <p>",
"         rHb2.0",
"        </p>",
"       </td>",
"       <td>",
"        Development halted",
"        <sup>",
"         [1]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"4\">",
"        Hgb-based: Human",
"       </td>",
"       <td rowspan=\"4\">",
"        Northfield Laboratories, Inc",
"       </td>",
"       <td rowspan=\"4\">",
"        PolyHeme",
"       </td>",
"       <td>",
"        Trauma trials \"more than 85 percent complete\"",
"        <sup>",
"         [2]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Company states informed consent approach compliant with Code of Federal Regulations",
"        <sup>",
"         [3]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acute normovolemic hemodilution trial observations published in company press release - states myocardial infarctions occurred in study subjects, none in controls",
"        <sup>",
"         [4]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Company shut down operations in 2009",
"        <sup>",
"         [5]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"3\">",
"        Hgb-based: Bovine",
"       </td>",
"       <td rowspan=\"3\">",
"        Biopure Corp",
"       </td>",
"       <td rowspan=\"3\">",
"        Hemopure",
"       </td>",
"       <td>",
"        Phase 3 US trials not yet approved by FDA pending safety review",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Selling Hemopure in S Africa",
"        <sup>",
"         [6]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Filed for bankruptcy, July 2009; sold assets to OPK Biotech LLC",
"        <sup>",
"         [7]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        PFC",
"       </td>",
"       <td rowspan=\"2\">",
"        Alliance Pharmaceutical",
"       </td>",
"       <td rowspan=\"2\">",
"        Oxygent",
"       </td>",
"       <td>",
"        Published results of European Phase 3 trial in non-cardiac patients",
"        <sup>",
"         [8]",
"        </sup>",
"        ; Preclinical study in cerebral blood flow likely to be presented to FDA in 2006 in preparation for possible future clinical trials in the US",
"        <sup>",
"         [9]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Announcement to partner with Double Crane Pharmaceutical Co. in China",
"        <sup>",
"         [10]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        PFC",
"       </td>",
"       <td>",
"        Hemosol, Inc",
"       </td>",
"       <td>",
"        Hemolink",
"       </td>",
"       <td>",
"        Not available - manufacturer declared bankruptcy, Nov 2005",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     Hgb: hemoglobin; PFC: perfluorochemical product.",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br>",
"      <ol>",
"       <li>",
"        Spahn, DR, Kocian, R. Artificial O2 carriers: status in 2005. Curr Pharm Des 2005; 11:4099.",
"       </li>",
"       <li>",
"        Northfield Laboratories Press Release. March 6, 2006.",
"       </li>",
"       <li>",
"        Northfield Laboratories Press Release. March 14, 2006.",
"       </li>",
"       <li>",
"        Northfield Laboratories Press Release. March 20, 2006.",
"       </li>",
"       <li>",
"        file://www.chicagotribune.com/business/chi-sat-northfield-0509-may09,0,1111961.story.",
"       </li>",
"       <li>",
"        PR Newswire - First Call. January 30, 2006.",
"       </li>",
"       <li>",
"        Biopure &mdash; Form D8K &mdash; Completion of Acquisition or Disposition of Assets. SEC 2009-08-24.",
"       </li>",
"       <li>",
"        Spahn, DR, Waschke, KF, Standl, T, et al. Use of perflubron emulsion to decrease allogeneic blood transfusion in high-blood-loss non-cardiac surgery: results of a European phase 3 study. Anesthesiology 2002; 97:1338.",
"       </li>",
"       <li>",
"        Alliance Pharmaceutical Corporation Press Release. April 20, 2006.",
"       </li>",
"       <li>",
"        file://www.thefreelibrary.com March 16, 2007.",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_40_10893=[""].join("\n");
var outline_f10_40_10893=null;
var title_f10_40_10894="Circular retinal fold";
var content_f10_40_10894=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F54434&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F54434&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Circular retinal fold in abusive head injury",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 251px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The fold extends inferiorly and superotemporally from the optic disk.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Kivlin, JD. Ophthalmic manifestations of shaken baby syndrome. Journal of Aggression, Maltreatment and Trauma 2001; 5:137. Copyright &copy;2001 The Haworth Press, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_40_10894=[""].join("\n");
var outline_f10_40_10894=null;
var title_f10_40_10895="LCH skull";
var content_f10_40_10895=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F64763&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F64763&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Langerhans cell histiocytosis of bone",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 344px; height: 357px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This axial computed tomography image of the head demonstrates a left-sided lytic skull lesion (arrowhead) with an associated soft tissue mass (arrow), representing a histopathologically-proven Langerhans cell histiocytosis (also known as eosinophilic granuloma).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_40_10895=[""].join("\n");
var outline_f10_40_10895=null;
